<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Neuropathol Commun</journal-id><journal-id journal-id-type="iso-abbrev">Acta Neuropathol Commun</journal-id><journal-title-group><journal-title>Acta Neuropathologica Communications</journal-title></journal-title-group><issn pub-type="epub">2051-5960</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6320585</article-id><article-id pub-id-type="publisher-id">655</article-id><article-id pub-id-type="doi">10.1186/s40478-018-0655-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>&#x02018;Dusty core disease&#x02019; (DuCD): expanding morphological spectrum of <italic>RYR1</italic> recessive myopathies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1830-2886</contrib-id><name><surname>Garibaldi</surname><given-names>Matteo</given-names></name><address><phone>+39 06 33775937</phone><email>matteo.garibaldi@uniroma1.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rendu</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Brocard</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lacene</surname><given-names>Emmanuelle</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Faur&#x000e9;</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Brochier</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beuvin</surname><given-names>Maud</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Labasse</surname><given-names>Clemence</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Madelaine</surname><given-names>Angeline</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Malfatti</surname><given-names>Edoardo</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bevilacqua</surname><given-names>Jorge Alfredo</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Lubieniecki</surname><given-names>Fabiana</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Monges</surname><given-names>Soledad</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Taratuto</surname><given-names>Ana Lia</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Laporte</surname><given-names>Jocelyn</given-names></name><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Antonini</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Romero</surname><given-names>Norma Beatriz</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label>Neuromuscular Morphology Unit, Myology Institute, Groupe Hospitalier Universitaire La Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, Paris, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.7841.a</institution-id><institution>Unit of Neuromuscular Diseases, Neuromuscular Disease Centre, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, </institution><institution>SAPIENZA University of Rome, </institution></institution-wrap>Sant&#x02019;Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0792 4829</institution-id><institution-id institution-id-type="GRID">grid.410529.b</institution-id><institution>Centre Hospitalier Universitaire de Grenoble Alpes, Biochimie G&#x000e9;n&#x000e9;tique et Mol&#x000e9;culaire, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0429 3736</institution-id><institution-id institution-id-type="GRID">grid.462307.4</institution-id><institution>Grenoble Institut des Neurosciences- Inserm U1216 &#x02013; UGA, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Sorbonne Universit&#x000e9;s UPMC Univ Paris 06- Inserm UMRS974, Center of Research in Myology, Institut de Myologie, Centre de R&#x000e9;f&#x000e9;rence Maladies Neuromusculaire Paris-Est-Ile de France, Groupe Hospitalier Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, </institution></institution-wrap>Paris, France </aff><aff id="Aff6"><label>6</label>Service Neurologie M&#x000e9;dicale, Centre de R&#x000e9;f&#x000e9;rence Maladies Neuromusculaire Paris-Est-Ile de France, CHU Raymond-Poincar&#x000e9; Paris Ouest, Garches, France </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2323 0229</institution-id><institution-id institution-id-type="GRID">grid.12832.3a</institution-id><institution>U1179 UVSQ-INSERM Handicap Neuromusculaire: Physiologie, Bioth&#x000e9;rapie et Pharmacologie appliqu&#x000e9;es, UFR des sciences de la sant&#x000e9; Simone Veil, Universit&#x000e9; Versailles-Saint-Quentin-en-Yvelines, </institution></institution-wrap>Versailles, France </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.412248.9</institution-id><institution>Neuromuscular Unit, Department of Neurology and Neurosurgery, </institution><institution>University of Chile Clinical Hospital, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 4466</institution-id><institution-id institution-id-type="GRID">grid.443909.3</institution-id><institution>Department of Anatomy and Legal Medicine, Faculty of Medicine, </institution><institution>University of Chile, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0695 6255</institution-id><institution-id institution-id-type="GRID">grid.414531.6</institution-id><institution>Servicio de Neurolog&#x000ed;a y Servicio de Patologia, Hospital de Pediatr&#x000ed;a Garrahan, </institution></institution-wrap>Buenos Aires, Argentina </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0620 9892</institution-id><institution-id institution-id-type="GRID">grid.418954.5</institution-id><institution>Neuropathology, Foundation for Neurological Research (FLENI), </institution></institution-wrap>Buenos Aires, Argentina </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0638 2716</institution-id><institution-id institution-id-type="GRID">grid.420255.4</institution-id><institution>Institut de G&#x000e9;n&#x000e9;tique et de Biologie Mol&#x000e9;culaire et Cellulaire (IGBMC), </institution></institution-wrap>1, rue Laurent Fries, BP 10142, 67404 Illkirch, France </aff><aff id="Aff13"><label>13</label>INSERM U1258, 67404 Illkirch, France </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0638 2716</institution-id><institution-id institution-id-type="GRID">grid.420255.4</institution-id><institution>CNRS, UMR7104, </institution></institution-wrap>67404 Illkirch, France </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution>Universit&#x000e9; de Strasbourg, </institution></institution-wrap>67404 Illkirch, France </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>7</volume><elocation-id>3</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Several morphological phenotypes have been associated to <italic>RYR1</italic>-recessive myopathies. We recharacterized the <italic>RYR1</italic>-recessive morphological spectrum by a large monocentric study performed on 54 muscle biopsies from a large cohort of 48 genetically confirmed patients, using histoenzymology, immunohistochemistry, and ultrastructural studies. We also analysed the level of RyR1 expression in patients&#x02019; muscle biopsies. We defined &#x0201c;dusty cores&#x0201d; the irregular areas of myofibrillar disorganisation characterised by a reddish-purple granular material deposition with uneven oxidative stain and devoid of ATPase activity, which represent the characteristic lesion in muscle biopsy in 54% of patients. We named Dusty Core Disease (DuCD) the corresponding entity of congenital myopathy. Dusty cores had peculiar histological and ultrastructural characteristics compared to the other core diseases. DuCD muscle biopsies also showed nuclear centralization and type1 fibre predominance. Dusty cores were not observed in other core myopathies and centronuclear myopathies. The other morphological groups in our cohort of patients were: Central Core (CCD: 21%), Core-Rod (C&#x00026;R:15%) and Type1 predominance &#x0201c;plus&#x0201d; (T1P+:10%). DuCD group was associated to an earlier disease onset, a more severe clinical phenotype and a lowest level of RyR1 expression in muscle, compared to the other groups. Variants located in the bridge solenoid and the pore domains were more frequent in DuCD patients. In conclusion, DuCD is the most frequent histopathological presentation of <italic>RYR1</italic>-recessive myopathies. Dusty cores represent the unifying morphological lesion among the DuCD pathology spectrum and are the morphological hallmark for the recessive form of disease.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s40478-018-0655-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>RYR1 recessive</kwd><kwd>Dusty Core Disease</kwd><kwd>Central Core Disease</kwd><kwd>Congenital Myopathy</kwd><kwd>Centronuclear myopathy</kwd><kwd>Ryanodine receptor</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004923</institution-id><institution>AFM-T&#x000e9;l&#x000e9;thon</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>JAB</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004271</institution-id><institution>Sapienza Universit&#x000e0; di Roma</institution></institution-wrap></funding-source><award-id>RM116154C9D1415B</award-id><principal-award-recipient><name><surname>Garibaldi</surname><given-names>Matteo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The <italic>RYR1</italic> gene encodes the ryanodine receptor channel 1 (RyR1), a sarcoplasmic reticulum (SR) calcium channel involved in excitation-contraction coupling through interaction with the dihydropyridine receptor (DHPR) in the T-tubule. <italic>RYR1</italic>-mutations are the most common cause of congenital myopathies with cores [<xref ref-type="bibr" rid="CR14">14</xref>]. Variable clinical and histological phenotypes have been described in both dominant and recessive forms [<xref ref-type="bibr" rid="CR36">36</xref>]. Dominant mutations in N-terminal and central regions (MHS/CCD1 and MHS/CCD2 domains respectively) are classically associated to Malignant Hyperthermia Susceptibility (MHS) trait, whereas dominant mutations in C-terminal region (MHS/CCD3) are more likely associated to Central Core Disease (CCD) [<xref ref-type="bibr" rid="CR40">40</xref>]. Moreover, heterozygous variants have been previously reported in core-rod myopathy [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and more recently in Exertional Rhabdomyolysis (ERM) [<xref ref-type="bibr" rid="CR9">9</xref>] and late-onset axial myopathy [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par3">By contrast, recessive forms of disease manifest a wider spectrum of clinical and histological presentations. Even if <italic>RYR1</italic>-recessive patients could present a clinical picture similar to the dominant one, including an early onset, non-progressive, proximal muscle weakness, other peculiar clinical phenotypes of recessive forms are characterized by a more diffuse muscle weakness, ocular involvement with ptosis and/or ophthalmoplegia, and a severe bulbar and respiratory muscle weakness [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Nevertheless, severe clinical presentations and foetal akinesia syndrome have been reported in both dominant and recessive forms [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par4">Concerning morphology, the phenotypic variability of histopathological findings in recessive forms increases even more, including CCD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], Multiminicore Disease (MmD) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], Congenital Fibre Type Disproportion (CFTD) [<xref ref-type="bibr" rid="CR7">7</xref>] and Centronuclear Myopathy (CNM) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Our group also described seven <italic>RYR1-</italic>recessive patients showing prominent nuclear internalization and large areas of myofibrillar disorganization [<xref ref-type="bibr" rid="CR4">4</xref>]. Despite this, in the largest review of 106 <italic>RYR1</italic>-recessive cases, up to 40% of patients did not fill these categories and were classified as Atypical Core Myopathy or different nonspecific histopathological groups [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par5">Recessive cases also present an increasing complexity, given the large amount of novel variants detected by the massive sequencing technologies, which makes the genotype-phenotype correlation more challenging. In general, hypomorphic variants (non-sense, frameshift, splice site variants), reducing or abolishing RyR1 production, seem to be more frequent in recessive forms and are associated to a more severe clinical presentation, compared to non-hypomorphic (missense, in-frame ins/del) variants [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Nevertheless, up to now, no association between clinical severity and histopathological findings has been found [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par6">We report an extensive monocentric analysis of 54 muscle biopsies from a large cohort of 48 <italic>RYR1</italic>-recessive patients to have a homogenous interpretation of morphological findings with the aim to find a closer correlation between morphology, clinical phenotype and genetic background. Here, we describe and define the &#x0201c;dusty core fibres&#x0201d; as the characteristic and unifying morphological feature present in most of <italic>RYR1</italic>-recesssive biopsies and we correlate the RyR1 expression level in patients&#x02019; muscle biopsies with clinical and morphological features.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients&#x02019; sample selection</title><p id="Par7">All the muscle biopsies were analysed at the Neuromuscular Morphology Unit of Myology Institute, in Paris. More than 11000 muscle biopsies collected between 1977 and 2015 were screened. Two hundred and thirty belonged to patients with <italic>RYR1</italic>-related myopathy, of whom 154 had dominant inheritance and 76 were confirmed or suspected to be recessive. In 13 cases the second variant was not found or was not surely pathogenetic (likely pathogenetic, VUS or likely benign). Among the 63 confirmed <italic>RYR1</italic>-recessive patients, 15 cases have been excluded because of insufficient data (uncomplete clinical and/or morphological data and deteriorated muscle sample for re-analysis). Finally, our study cohort consisted on 48 confirmed <italic>RYR1</italic>-recessive patients (20 male and 28 female) from 45 unrelated families. Clinical data were obtained from a full revision of all available medical records up to the last clinical examination in all enrolled patients. Disease onset (considered as the first reported clinical sign referred to disease, including perinatal problems or delayed motor milestones), weakness distribution (proximal/distal limb muscles, axial, facial, ocular/extraocular and bulbar muscles), contractures, spinal deformities and dysmorphisms, respiratory and cardiac involvement were considered. Clinical evaluations were performed by different clinicians over 40 years, thus we retrospectively classified patients in three main groups of clinical severity: mild (late-adult onset, walkers, mild muscle weakness, minimal or absent ocular, facial, bulbar or respiratory involvement), moderate (early onset, non-progressive, proximal or diffuse muscle weakness, associate with mild dysmorphism, spine deformities or contractures) and severe (muscle hypotonia at birth, feeding difficulties, severe respiratory involvement requiring ventilation, contractures and/or spinal deformities, diffuse muscle weakness with facial and ocular involvement).</p></sec><sec id="Sec4"><title>Genetic analysis</title><p id="Par8">Total RNA was extracted from each skeletal muscle sample lysed in Trizol reagent (Invitrogen, Life Technologies SAS). Complementary DNA was synthesized from 500 to 750 ng of total RNA using 0.5 &#x003bc;l of Transcriptor (Roche) and 0.3 lg of oligo-dT as described [<xref ref-type="bibr" rid="CR26">26</xref>]. Seven overlapping PCR amplification spanning the entire <italic>RYR1</italic> sequence were performed. Each fragment was sequenced as previously described [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Each variation was confirmed on DNA sample and on both paternal and maternal DNA sample to establish the transmission. Each variant was analysed by Variant effect Predictors to obtain the different prediction score such as CADD, SIFT, Polyphen and gnomAD exome and gnomAD Genome database frequency. To better assess the functional effect of each missense variation, 3D analysis was performed on Yasara sofware [<xref ref-type="bibr" rid="CR21">21</xref>]. Due to the large size of the <italic>RYR1</italic> gene, we choose not to use the total RyR1 protein structure already described (5gl1/5taz) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] in the first-round analysis via FoldX prediction. We choose to split the structure in 5 parts spanning the whole human RYR1 structures (amino acid 1 to 627, 628 to 1656, 1657 to 2144, 2145 to 3613 and 3614 to 5038). Then, the sequences were submitted in I-TASSER server [<xref ref-type="bibr" rid="CR39">39</xref>] to obtain &#x0201c;friendly&#x0201d; usable RyR1 structure. Each structure prediction was matched with the RyR1 global structure (5gl1 and 5taz) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Delta G variations were calculated to estimate protein stability. For delta G variation &#x0003c;0.5 kcal/mol, meaning no destabilization, study of the whole structure was realized (5gl1/5taz) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. For ACMG classification, Intervar was used with recessive transmission correction [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec5"><title>Histological study</title><p id="Par9">Histoenzymological analysis was conducted on 54 muscle biopsies (4 patients had two muscle biopsies and 1 patient three muscle biopsies available in the Myology Institute Lab). Age at muscle biopsy ranged from 1 day of life (30 weeks of adjusted gestational age) to 76 years (median 16 years, IQR 3-34). Open muscle biopsies were obtained from deltoid or quadriceps muscles in most of patients. Histological and histochemical slides were systematically re-analysed by two authors (MG and NBR) with experience in skeletal muscle morphology, blinded to clinical and molecular data. For the oldest, deteriorated or not interpretable slides, new slides were obtained from the best muscle specimen available in the lab. Conventional histological and histochemical techniques, 8-10 &#x003bc;m thick cryostat sections were stained with haematoxylin and eosin (HE), modified Gomori trichrome (GT), Periodic acid Schiff technique (PAS), Oil red O, reduced nicotinamide adenine dinucleotide dehydrogenase-tetrazolium reductase (NADH-TR), succinic dehydrogenase (SDH), cytochrome c oxidase (COX), and adenosine triphosphatase (ATPase) preincubated at pH 9.4, 4.63, 4.35. Digital photographs of biopsies were obtained with a Zeiss AxioCam HRc linked to a Zeiss Axioplan Bright Field Microscope and processed with the Axio Vision 4.4 software (Zeiss, Germany). Fibre type pattern was determined in ATPases reactions, and by calculating the percentage of type 1 and type 2 fibres. We considered type 1 fibres predominance when there were more than of 60% type 1 fibre in deltoid muscles, and more than 40% in quadriceps muscle. CFTD was considered when all the type1 fibres were consistently (at least 35-40%) smaller than type2 fibres in absence of other pathological findings. Centronuclear pattern was considered only when myonuclei were centrally placed in almost 50% of muscle fibres showing nuclear internalization. Rods were considered in the presence of numerous, multiple, small nemaline bodies both in cytoplasmic or subsarcolemmal areas. Central cores were considered when single or multiple sharply demarked ovoidal areas devoid of oxidative stains were observed in transversal sections of type1 muscle fibres, centrally or peripherally placed. Multiminicore were considered in the presence of boundless, small areas of decreased enzymatic activity at oxidative stains [<xref ref-type="bibr" rid="CR30">30</xref>]. &#x0201c;Dusty cores&#x0201d; were defined as irregular areas of reddish-purple granular material deposition at GT stain corresponding to decreased or/and increased enzymatic activity at oxidative stains and devoid of ATPase activity. Patients with available ultrastructural study were finally classified considering both histological and ultrastructural features. In the five patients with two or three muscle biopsies, final morphological classification was reached considering both muscle biopsies and most relevant findings.</p></sec><sec id="Sec6"><title>Immunohistochemical (IHC) study</title><p id="Par10">IHC was performed in new sections from available frozen muscle samples of enrolled patients, rejecting oldest and/or deteriorated specimens. Finally, IHC analysis was available for 23 muscle biopsies. Antibodies against Desmin (Anti-Human Desmin, Clone D33, Dako Laboratories, Denmark A/S ), Myotilin (NCL-Myotilin, Novocastra Laboratories, Newcastle Upon Tyne, United Kingdom) and &#x003b1;B-crystallin (CRYAB, GeneTex International Corporation, Irvine, USA) were visualized using immunoperoxidase techniques. Immunofluorescence study was performed for RyR (anti-Ryanodine Receptor, clone 34C, Sigma Laboratories, Saint Louis, Missouri, USA), DHPR (anti-CACNA1S, ab2862, abcam Laboratories, Cambridge, UK) and alpha-actinin (anti-&#x003b1; actinin sarcomeric, clone EA-53, Sigma Aldrich Laboratories, Saint Louis, USA) antibodies on 10-&#x003bc;m-thick cryosections over night at 4&#x000b0;C. Subsequently, sections were incubated with appropriate conjugated secondary antibodies (Alexa Fluor-488 goat anti-rabbit antibody and Jackson IR goat anti-mouse antibody) for one hour. A set of control slides was prepared with omission of the primary antibodies.</p></sec><sec id="Sec7"><title>Electron microscopy (EM) study</title><p id="Par11">Ultrastructural study was newly performed in all available muscle biopsies. EM images were obtained for 39 muscle biopsies. Small muscle specimens were fixed with glutaraldehyde (2.5%, pH 7.4), post fixed with osmium tetroxide (2%), dehydrated and embedded in resin. Longitudinally oriented ultra-thin sections were obtained at different level of deepness from 1 to 3 small blocks and stained with uranyl acetate and lead citrate. Ultra-thin sections of transversally oriented blocks were obtained only for the most significant findings. The grids were observed using a Philips CM120 electron microscope (80 kV; Philips Electronics NV, Eindhoven, The Netherlands) and were photo documented using a Morada camera (Soft Imaging System).</p></sec><sec id="Sec8"><title>Western blot (WB) analysis</title><p id="Par12">The amount of RyR1 in muscle samples was determined by quantitative Western Blot (WB) analysis using antibodies directed against RyR1 [<xref ref-type="bibr" rid="CR24">24</xref>] and normalized to the amount of myosin heavy chain as described previously [<xref ref-type="bibr" rid="CR26">26</xref>]. Briefly, the muscle sample (20-40mg) was homogenized in 200 mM sucrose, 20mM HEPES (pH 7.4), 0.4mMCaCl2, 200mM phenylmethylsulfonyl fluoride, 1 mM diisopropyl Fluorophosphate using a Minilys homogenizer (Bertin, France). After electrophoretic separation on a 4&#x02013;20% gradient acrylamide gel (Biorad, France) and electrotransfer to Immobilon P (Biorad, France) during 4h at 0.8A to ensure a complete transfer of the loaded proteins, the membrane was incubated with anti-RyR1 antibodies and then HRP-labelled secondary antibodies (Jackson ImmunoResearch Laboratories). Signal quantification was performed using a ChemiDoc Touch apparatus (Biorad, France) and the Image Lab software (Biorad). The total amount of RyR1 in each experiment was corrected from the amount of myosin and normalized to the amount of RyR1 present in the control referred as 100% as described previously [<xref ref-type="bibr" rid="CR6">6</xref>]. Controls (muscle biopsy from individuals non-affected by neuromuscular disease) of different age have been used: 10 days, 3 years, 23 years and 46 years, and the amount of RyR1 in the muscle biopsy of the patient was compared to the age-related control. For each muscle biopsy, at least 3 western blots have been performed, and the value for each patient is presented as mean &#x000b1; SEM of the different western blots.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par13">Data have been expressed as range, median and interquartile range (IQR) for continuous variables (age and % of RyR expression) and as absolute values and frequencies for categorical variables (gender, disease severity, age at onset, morphology and occurrence of ocular involvement). Age at disease onset has been categorized as &#x0003c;1 year or &#x02265;1 year, based on the median value in the sample. Chi-Square test has been used to compare categorical variables, while Kruskal-Wallis or Mann-Whitney tests have been used to evaluate the distribution of continuous variables with respect to demographic, clinical and morphological characteristics. P values lower than 0.05 were considered to be statistically significant. Statistical Package for Social Science (SPSS&#x000ae;) version 20.0 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) was used for statistical analysis.</p></sec></sec><sec id="Sec10"><title>Results</title><p id="Par14">Overall morphological, clinical and genetic data are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Morphological, clinical and genetic data overview</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Revised Morphology</th><th>Clinical Severity</th><th>Allele 1</th><th>Allele 2</th><th>RYR1<break/>(WB)</th><th>Ref.</th></tr></thead><tbody><tr><td>p1</td><td>DuCD</td><td>severe</td><td>c.3223C&#x0003e;T</td><td>c.7025A&#x0003e;G</td><td>39%</td><td>this report</td></tr><tr><td>p2</td><td>DuCD</td><td>moderate</td><td>c.8692+131G&#x0003e;A</td><td>c.8692+131G&#x0003e;A</td><td>25%</td><td>[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td>p3</td><td>DuCD</td><td>moderate</td><td>c.9413C&#x0003e;T</td><td>c.11314C&#x0003e;T</td><td>34%</td><td>this report</td></tr><tr><td>p4</td><td>DuCD</td><td>severe</td><td>c.9758T&#x0003e;C</td><td>c.8953C&#x0003e;T</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td>p5</td><td>DuCD</td><td>severe</td><td>c.14170A&#x0003e;C</td><td>c.13949T&#x0003e;C</td><td>n.a.</td><td>this report</td></tr><tr><td>p6</td><td>DuCD</td><td>mild</td><td>c.14731G&#x0003e;A</td><td>c.7006C&#x0003e;T</td><td>25%</td><td>this report</td></tr><tr><td>p7</td><td>DuCD</td><td>mild</td><td>c.14731G&#x0003e;A</td><td>c.10616G&#x0003e;A</td><td>56%</td><td>this report</td></tr><tr><td>p8</td><td>DuCD</td><td>mild</td><td>c.631+1G&#x0003e;A</td><td>c.14717C&#x0003e;T</td><td>n.a.</td><td>this report</td></tr><tr><td>p9</td><td>DuCD</td><td>severe</td><td>c.13660- ?_14646- ?del987nt.</td><td>c.10348-6C&#x0003e;G; c.14524G&#x0003e;A</td><td>7%</td><td>[<xref ref-type="bibr" rid="CR1">1</xref>]</td></tr><tr><td>p10</td><td>DuCD</td><td>moderate</td><td>c.10561G&#x0003e;T</td><td>c.9605C&#x0003e;T</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td>p11</td><td>DuCD</td><td>mild</td><td>c.325C&#x0003e;T</td><td>c.6891+1G&#x0003e;T</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR1">1</xref>]</td></tr><tr><td>p12</td><td>DuCD</td><td>severe</td><td>c.14524G&#x0003e;A; c.10348-6C&#x0003e;G</td><td>c.8342_8343delTA</td><td>18%</td><td>[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td>p13</td><td>DuCD</td><td>moderate</td><td>c.11999_12001del</td><td>c.6933delC</td><td>25%</td><td>this report</td></tr><tr><td>p14</td><td>DuCD</td><td>moderate</td><td>c.6418C&#x0003e;T</td><td>c.14483T&#x0003e;G</td><td>37%</td><td>this report</td></tr><tr><td>p15</td><td>DuCD</td><td>moderate</td><td>c.6418C&#x0003e;T</td><td>c.14483T&#x0003e;G</td><td>32%</td><td>this report</td></tr><tr><td>p16</td><td>DuCD</td><td>mild</td><td>c.7372C&#x0003e;T</td><td>c.1897C&#x0003e;T</td><td>60%</td><td>this report</td></tr><tr><td>p17</td><td>DuCD</td><td>mild</td><td>c.2648T&#x0003e;C</td><td>c.9157C&#x0003e;T</td><td>n.a.</td><td>this report</td></tr><tr><td>p18</td><td>DuCD</td><td>mild</td><td>c.4711A&#x0003e;G;c.10097G&#x0003e;A;c.11798A&#x0003e;G</td><td>c.2361delG</td><td>33%</td><td>this report</td></tr><tr><td>p19</td><td>DuCD</td><td>mild</td><td>c.4225C&#x0003e;T</td><td>c.14126C&#x0003e;T</td><td>23%</td><td>this report</td></tr><tr><td>p20</td><td>DuCD</td><td>moderate</td><td>c.7615-3T&#x0003e;A</td><td>duplication at least exon 99-106</td><td>25%</td><td>this report</td></tr><tr><td>p21</td><td>DuCD</td><td>mild</td><td>c.4711A&#x0003e;G;c.10097G&#x0003e;A;c.11798A&#x0003e;G</td><td>c.14731G&#x0003e;A</td><td>n.a.</td><td>this report</td></tr><tr><td>p22</td><td>DuCD</td><td>moderate</td><td>c.14939C&#x0003e;T</td><td>c.12541G&#x0003e;A</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td>p23</td><td>DuCD</td><td>mild</td><td>c.9892G&#x0003e;A</td><td>c.4953_4970dup</td><td>18%</td><td>this report</td></tr><tr><td>p24</td><td>DuCD</td><td>severe</td><td>c.644G&#x0003e;A</td><td>c.1840C&#x0003e;T</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>p25</td><td>DuCD</td><td>mild</td><td>c.6721C&#x0003e;T</td><td>c.7268T&#x0003e;A</td><td>42%</td><td>this report</td></tr><tr><td>p26</td><td>DuCD+CCD</td><td>mild</td><td>c.4711A&#x0003e;G;c.10097G&#x0003e;A;c.11798A&#x0003e;G</td><td>c.14537C&#x0003e;T</td><td>63%</td><td>this report</td></tr><tr><td>p27</td><td>CCD</td><td>mild</td><td>c.6617C&#x0003e;T</td><td>c.6617C&#x0003e;T</td><td>76%</td><td>this report</td></tr><tr><td>p28</td><td>CCD</td><td>mild</td><td>c.7304G&#x0003e;T</td><td>c.7304G&#x0003e;T</td><td>n.a.</td><td>this report</td></tr><tr><td>p29</td><td>CCD</td><td>mild</td><td>c.13502C&#x0003e;T</td><td>c.14386T&#x0003e;C</td><td>40%</td><td>this report</td></tr><tr><td>p30</td><td>CCD</td><td>mild</td><td>c.11708G&#x0003e;A</td><td>c.11708G&#x0003e;A</td><td>45%</td><td>this report</td></tr><tr><td>p31</td><td>CCD</td><td>severe</td><td>c.10348-6C&#x0003e;G; c.14524G&#x0003e;A</td><td>c.7324-1G&#x0003e;T</td><td>14%</td><td>[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td>p32</td><td>CCD</td><td>mild</td><td>c.2938C&#x0003e;T</td><td>c.7372C&#x0003e;T</td><td>47%</td><td>this report</td></tr><tr><td>p33</td><td>CCD</td><td>mild</td><td>c.4711A&#x0003e;G;c.10097G&#x0003e;A;c.11798A&#x0003e;G</td><td>c.13691G&#x0003e;A</td><td>n.a.</td><td>this report</td></tr><tr><td>p34</td><td>CCD</td><td>moderate</td><td>c.212C&#x0003e;A</td><td>c.6847A&#x0003e;C</td><td>n.a.</td><td>this report</td></tr><tr><td>p35</td><td>CCD</td><td>moderate</td><td>c.5036G&#x0003e;A</td><td>c.464A&#x0003e;C</td><td>51%</td><td>this report</td></tr><tr><td>p36</td><td>CCD</td><td>mild</td><td>c.14126C&#x0003e;T</td><td>c.7063C&#x0003e;T</td><td>52%</td><td>this report</td></tr><tr><td>p37</td><td>C&#x00026;R</td><td>mild</td><td>c.4711A&#x0003e;G;c.10097G&#x0003e;A;c.11798A&#x0003e;G</td><td>c.2984G&#x0003e;A</td><td>60%</td><td>this report</td></tr><tr><td>p38</td><td>C&#x00026;R</td><td>mild</td><td>c.10579C&#x0003e;T</td><td>c.10579C&#x0003e;T</td><td>n.a.</td><td>this report</td></tr><tr><td>p39</td><td>C&#x00026;R</td><td>mild</td><td>c.14928C&#x0003e;G</td><td>c.4711A&#x0003e;G;c.9356G&#x0003e;A;c.10097G&#x0003e;A;c.11798A&#x0003e;G</td><td>57%</td><td>this report</td></tr><tr><td>p40</td><td>C&#x00026;R</td><td>moderate</td><td>c.14624T&#x0003e;C</td><td>c.3619G&#x0003e;A</td><td>20%</td><td>this report</td></tr><tr><td>p41</td><td>C&#x00026;R</td><td>mild</td><td>c.14731G&#x0003e;A</td><td>c.6359T&#x0003e;C</td><td>52%</td><td>this report</td></tr><tr><td>p42</td><td>C&#x00026;R</td><td>mild</td><td>c.11557G&#x0003e;A</td><td>c.115G&#x0003e;A</td><td>52%</td><td>this report</td></tr><tr><td>p43</td><td>C&#x00026;R</td><td>severe</td><td>c.14928C&#x0003e;G</td><td>c.2044C&#x0003e;T</td><td>n.a.</td><td>this report</td></tr><tr><td>p44</td><td>T1P+</td><td>moderate</td><td>c.12536G&#x0003e;A</td><td>c.9605C&#x0003e;T</td><td>54%</td><td>this report</td></tr><tr><td>p45</td><td>T1P+</td><td>moderate</td><td>c.6860C&#x0003e;A</td><td>c.14939C&#x0003e;T</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td>p46</td><td>T1P+</td><td>mild</td><td>c.10579C&#x0003e;T</td><td>c.10579C&#x0003e;T</td><td>n.a.</td><td>[<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td>p47</td><td>T1P+</td><td>moderate</td><td>c.10579C&#x0003e;T</td><td>c.10579C&#x0003e;T</td><td>n.a.</td><td>this report</td></tr><tr><td>p48</td><td>T1P+</td><td>moderate</td><td>c.12861_12869dupCACGGCGGC</td><td>c.12861_12869dupCACGGCGGC</td><td>79%</td><td>this report</td></tr></tbody></table><table-wrap-foot><p><italic>DuCD</italic> Dusty core disease, <italic>CCD</italic> Central core disease, <italic>C&#x00026;R</italic> Core-rod myopathy, <italic>T1P+</italic> Type1 predominance &#x0201c;plus&#x0201d;, <italic>n.a.</italic> Not assessed</p></table-wrap-foot></table-wrap></p><sec id="Sec11"><title>Clinical features</title><p id="Par15">Age at onset ranged from antenatal period to 66 years (median 1 year, IQR 0-7). The first symptom/sign occurred within the first year of life in 23 patients (48%), of whom five had also antenatal manifestation. Disease onset occurred after the first year of life in 25 patients (52%) of whom 4 had a relative late onset (&#x0003e;20 years). Motor milestones were delayed in 25 patients (52%) and 4 out of 8 severe patients never acquired ambulation. All the patients with latest onset (&#x0003e;45 years) had not delayed motor milestones, as well as 9 (19%) with early-infantile onset. Ocular involvement was assessed in 38 of 48 patients and showed isolated eyelid ptosis in 4 patients, isolated ophthalmoplegia (sometimes isolated upper gaze movements) in 7 and both in 9. Overall, ocular involvement occurred in 20/38 patients and prevailed in subjects with moderate/severe disease (88%) compared to those with mild disease (24%) (<italic>p</italic>&#x0003c;0.0001). Overall clinical severity was mild in 25 (52%), moderate in 15 (31%) and severe in 8 patients (17%). All the clinical data are summarised in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical features</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Family</th><th>Age onset</th><th>Sex</th><th>Age at last examination</th><th>Perinatal problems</th><th>Delayed motor milestones</th><th>Ocular involvement</th><th>Muscle weakness</th><th>Other clinical features</th><th>Respiratory involvement</th><th>Spine deformities</th><th>Contractures</th><th>Dysmorphism</th></tr></thead><tbody><tr><td>p1</td><td>f1</td><td>B</td><td>m</td><td>45 ds</td><td>H; FP; RI</td><td>NW</td><td>Pt + Oph</td><td>G++,</td><td>-</td><td>+++</td><td>-</td><td/><td>-</td></tr><tr><td>p2</td><td>f2</td><td>2 ys</td><td>m</td><td>30 ys</td><td>n.r.</td><td>yes</td><td>Oph</td><td>G, F, SW</td><td>-</td><td>++</td><td>-</td><td>CFee</td><td>LNF; HAP</td></tr><tr><td>p3</td><td>f3</td><td>B</td><td>m</td><td>21 ys</td><td>RD</td><td>no</td><td>Pt + Oph</td><td>d&#x0003e;p LL, d/p UL</td><td>-</td><td>-</td><td>-</td><td>AcR</td><td>LNF; PrG</td></tr><tr><td>p4</td><td>f4</td><td>B</td><td>f</td><td>12 ws</td><td>H; FP; RI</td><td>yes</td><td>no</td><td>G, F,</td><td>-</td><td>+++</td><td>Sc</td><td>H; Kn</td><td>-</td></tr><tr><td>p5</td><td>f5</td><td>B</td><td>f</td><td>1 ys</td><td>H; FP; RI, Art</td><td>yes</td><td>Pt</td><td>F, pUL/LL,</td><td>-</td><td>++</td><td>-</td><td>-</td><td>RtG</td></tr><tr><td>p6</td><td>f6</td><td>B</td><td>f</td><td>16 ys</td><td>FP</td><td>yes</td><td>no</td><td>F, A, pUL/LL, dUL,</td><td>Dph</td><td>-</td><td>-</td><td>-</td><td>LNF; HAP;</td></tr><tr><td>p7</td><td>f7</td><td>60 ys</td><td>m</td><td>76 ys</td><td>no</td><td>no</td><td>Oph</td><td>F, A, pUL, dUL&#x0003e;LL,</td><td>Dph</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p8</td><td>f8</td><td>2 ys</td><td>f</td><td>27 ys</td><td>no</td><td>yes</td><td>no</td><td>G, F</td><td>EI</td><td>+</td><td>Sc, Ld</td><td>-</td><td>HAP, RtG,</td></tr><tr><td>p9</td><td>f9</td><td>A</td><td>m</td><td>7 ys</td><td>O</td><td>yes</td><td>Pt + Oph</td><td>F, A, pUL/LL</td><td>Dph, CH</td><td>-</td><td>-</td><td>pUL HypL</td><td>PctE</td></tr><tr><td>p10</td><td>f10</td><td>B</td><td>f</td><td>34y</td><td>n.r.</td><td>n.r.</td><td>Oph (UG only)</td><td>G, F,</td><td>SW</td><td>++</td><td>Sc; Ld; SpB</td><td>AcR; H; Kn HypL;</td><td>-</td></tr><tr><td>p11</td><td>f11</td><td>B</td><td>m</td><td>48y</td><td>FP</td><td>n.r.</td><td>Pt + Oph</td><td>G, F,</td><td>-</td><td>+</td><td>Sc</td><td>-</td><td>LNF; HAP</td></tr><tr><td>p12</td><td>f12</td><td>B</td><td>f</td><td>4 ys</td><td>H; RI</td><td>yes</td><td>Pt + Oph</td><td>G, F,</td><td>PP</td><td>++</td><td>yes?</td><td>AcR; H, Kn;</td><td>HAP</td></tr><tr><td>p13</td><td>f13</td><td>B</td><td>f</td><td>29 ys</td><td>H</td><td>n.r.</td><td>Pt + Oph</td><td>G, F,</td><td>Dph</td><td>-</td><td>-</td><td>-</td><td>LNF</td></tr><tr><td>p14</td><td>f14</td><td>B</td><td>f</td><td>10 ys</td><td>H; FP, HD</td><td>yes</td><td>n.r.</td><td>pLL</td><td>Gowers</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p15</td><td>f14</td><td>B</td><td>f</td><td>3 ys</td><td>H; FP, HD</td><td>yes</td><td>n.r.</td><td>pLL</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p16</td><td>f15</td><td>10 ys</td><td>f</td><td>69 ys</td><td>no</td><td>no</td><td>no</td><td>p/ dLL</td><td>Gowers</td><td>-</td><td>-</td><td>AcR</td><td>-</td></tr><tr><td>p17</td><td>f16</td><td>6 mo</td><td>f</td><td>34 ys</td><td>no</td><td>yes</td><td>no</td><td>A, pUL,</td><td>CH</td><td>+</td><td>Ld; Sc</td><td>-</td><td>-</td></tr><tr><td>p18</td><td>f17</td><td>20 ys</td><td>f</td><td>26 ys</td><td>n.r.</td><td>yes</td><td>no</td><td>F, A, p/d LL</td><td>EI</td><td>-</td><td>no</td><td>-</td><td>-</td></tr><tr><td>p19</td><td>f18</td><td>1 ys</td><td>m</td><td>4ys</td><td>no</td><td>yes</td><td>Pt</td><td>F, A, pLL</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p20</td><td>f19</td><td>B</td><td>m</td><td>25 ys</td><td>H;</td><td>yes</td><td>Oph</td><td>G, F</td><td>Dph</td><td>++</td><td>-</td><td>TFL; H; Kn; T-M</td><td>LNF; HAP</td></tr><tr><td>p21</td><td>F20</td><td>1 yr</td><td>f</td><td>5 ys</td><td>no</td><td>yes</td><td>no</td><td>F, pLL&#x0003e;UL</td><td>-</td><td>-</td><td>no</td><td>G HypL</td><td>No</td></tr><tr><td>p22</td><td>f21</td><td>A</td><td>f</td><td>25 ys</td><td>no</td><td>yes</td><td>Oph</td><td>A, pLL&#x0003e;UL, dUL/LL,</td><td>Dpg; Dph</td><td>+++</td><td>Ld</td><td>RSs; finger ext; Eb; AcR</td><td>LNF; HAP</td></tr><tr><td>p23</td><td>f22</td><td>1 ys</td><td>m</td><td>8 ys</td><td>no</td><td>yes</td><td>no</td><td>F, pUL/LL</td><td>-</td><td>-</td><td>Ld</td><td>-</td><td>-</td></tr><tr><td>p24</td><td>f23</td><td>A</td><td>m</td><td>6 ys</td><td>PO, FAS</td><td>NW</td><td>Pt + Oph</td><td>G, F</td><td>CD</td><td>-</td><td>-</td><td>G</td><td>-</td></tr><tr><td>p25</td><td>f24</td><td>1 ys</td><td>m</td><td>43 ys</td><td>no</td><td>yes</td><td>Oph (UG only)</td><td>F, pUL/LL, dUL</td><td>-</td><td>-</td><td>-</td><td>Kn</td><td>-</td></tr><tr><td>p26</td><td>f25</td><td>10 ys</td><td>f</td><td>32 ys</td><td>no</td><td>no</td><td>no</td><td>F, A, pUL/LL</td><td>Gowers</td><td>-</td><td>no</td><td>-</td><td>-</td></tr><tr><td>p27</td><td>f26</td><td>6 ys</td><td>f</td><td>16 ys</td><td>no</td><td>no</td><td>n.r.</td><td>A</td><td>-</td><td>-</td><td>Ky</td><td>-</td><td>-</td></tr><tr><td>p28</td><td>f27</td><td>1 ys</td><td>f</td><td>8 ys</td><td>no</td><td>no</td><td>n.r.</td><td>pLL</td><td>t-tW; Gowers</td><td>-</td><td>Ld; Sc</td><td>AcR; Pes cavus</td><td>-</td></tr><tr><td>p29</td><td>f28</td><td>1 ys</td><td>m</td><td>23 ys</td><td>no</td><td>yes</td><td>no</td><td>A, pLL&#x0003e;UL</td><td>-</td><td>-</td><td>-</td><td>AcR</td><td>-</td></tr><tr><td>p30</td><td>f29</td><td>1 ys</td><td>f</td><td>5 ys</td><td>no</td><td>yes</td><td>no</td><td>A, pUL/LL,</td><td>-</td><td>++</td><td>Ld</td><td>AcR</td><td>-</td></tr><tr><td>p31</td><td>f30</td><td>B</td><td>m</td><td>n.r.</td><td>H; FP; Art</td><td>NW</td><td>Pt + Oph</td><td>G, F,</td><td>-</td><td>+++</td><td>yes</td><td>Kn; Eb; H; distal HypL</td><td>-</td></tr><tr><td>p32</td><td>f31</td><td>45 ys</td><td>m</td><td>52 ys</td><td>no</td><td>no</td><td>no</td><td>pLL</td><td>CH</td><td>-</td><td>-</td><td>-</td><td>no</td></tr><tr><td>p33</td><td>f32</td><td>8 ys</td><td>f</td><td>49 ys</td><td>no</td><td>yes</td><td>no</td><td>F, A, pLL/UL</td><td>-</td><td>-</td><td>Sc</td><td>-</td><td>no</td></tr><tr><td>p34</td><td>f33</td><td>B</td><td>m</td><td>5 ys</td><td>HD</td><td>yes</td><td>n.r.</td><td>pLL</td><td>Gowers</td><td>-</td><td>Ld</td><td>AcR</td><td>-</td></tr><tr><td>p35</td><td>f34</td><td>8 ys</td><td>m</td><td>37 ys</td><td>no</td><td>n.r.</td><td>no</td><td>A, pUL/LL, dLL,</td><td>Dph, t-tW</td><td>+</td><td>Sc</td><td>-</td><td>-</td></tr><tr><td>p36</td><td>f35</td><td>66 ys</td><td>f</td><td>76 ys</td><td>no</td><td>no</td><td>no</td><td>A, pLL</td><td>-</td><td>-</td><td>-</td><td>-</td><td>no</td></tr><tr><td>p37</td><td>f36</td><td>10 ys</td><td>f</td><td>62 ys</td><td>no</td><td>n.r.</td><td>n.r.</td><td>pLL/UL, dUL</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p38</td><td>f37</td><td>5 ys</td><td>f</td><td>21 ys</td><td>no</td><td>no</td><td>no</td><td>F, pUL/LL</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p39</td><td>f38</td><td>8 ys</td><td>f</td><td>63 ys</td><td>no</td><td>no</td><td>no</td><td>A, pLL&#x0003e;UL, dUL,</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p40</td><td>f39</td><td>B</td><td>f</td><td>26 ys</td><td>H; FP, HD, CFee</td><td>yes</td><td>n.r.</td><td>A, pUL/LL,</td><td>-</td><td>+</td><td>Sc</td><td>AcR</td><td>-</td></tr><tr><td>p41</td><td>f40</td><td>8 ys</td><td>m</td><td>33 ys</td><td>no</td><td>n.r.</td><td>n.r.</td><td>pUL/LL</td><td>SW</td><td>-</td><td>-</td><td>AcR</td><td>-</td></tr><tr><td>p42</td><td>f41</td><td>1 ys</td><td>m</td><td>13 ys</td><td>n.r.</td><td>n.r.</td><td>no</td><td>A, pLL</td><td>-</td><td>-</td><td>Ld</td><td>-</td><td>-</td></tr><tr><td>p43</td><td>f42</td><td>A</td><td>f</td><td>1 d</td><td>Art, (death 1 day)</td><td>NW</td><td>n.r.</td><td>G,</td><td>LH</td><td>+++</td><td>-</td><td>Art</td><td>-</td></tr><tr><td>p44</td><td>f43</td><td>B</td><td>m</td><td>3 ys</td><td>FP</td><td>no</td><td>Pt</td><td>G</td><td>Gowers</td><td>-</td><td>-</td><td>distal and Eb HypL</td><td>HAP</td></tr><tr><td>p45</td><td>f44</td><td>1 ys</td><td>f</td><td>15 ys</td><td>Art</td><td>yes</td><td>Pt + Oph</td><td>A, pUL/LL</td><td>CH</td><td>-</td><td>Ld; Sc</td><td>-</td><td>-</td></tr><tr><td>p46</td><td>F37</td><td>B</td><td>f</td><td>42 ys</td><td>H</td><td>yes</td><td>Oph</td><td>G, F,</td><td>-</td><td>+</td><td>-</td><td>T-M; distal HypL</td><td>HAP</td></tr><tr><td>p47</td><td>F37</td><td>3 ys</td><td>f</td><td>4 ys</td><td>no</td><td>no</td><td>n.r.</td><td>pUL/LL</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>p48</td><td>f45</td><td>B</td><td>m</td><td>19 ys</td><td>H</td><td>yes</td><td>Pt</td><td>G, F,</td><td>HL</td><td>+++</td><td>Sc</td><td>CFee</td><td>-</td></tr></tbody></table><table-wrap-foot><p><italic>B</italic> At birth, <italic>A</italic> Antenatal, <italic>H</italic> Hypotonia, <italic>RI</italic> Respiratory insufficiency, <italic>FP</italic> Feeding problems, <italic>O</italic> Oligohydramnios, <italic>PO</italic> Polyhydramnios, <italic>FAS</italic> Fetal akinesia syndrome, <italic>NW</italic> Never walk, <italic>Art</italic> Arthrogryposis, <italic>HD</italic> Hip dysplasia, <italic>Pt</italic> Eyelid ptosis, <italic>Oph</italic> Ophthalmoplegia, <italic>UG</italic> Upper gaze, <italic>G</italic> Generalized, <italic>SW</italic> Scapular winging, <italic>d</italic> Distal, <italic>p</italic> Proximal, <italic>UL</italic> Upper limbs, <italic>LL</italic> Lower limbs, <italic>F</italic> Facial, <italic>Ax</italic> Axial, <italic>Dph</italic> Dysphonia, <italic>Dpg</italic> Dysphagia, <italic>EI</italic> Exercise intolerance, <italic>CH</italic> Calf hypertrophy, <italic>PP</italic> Precocious puberty, <italic>CD</italic> Cognitive delay, <italic>t-tW</italic> Tip-toe walking, <italic>HL</italic> Hearing loss, <italic>LH</italic> Lung hypoplasia, <italic>Sc</italic> Scoliosis, <italic>Ld</italic> Lordosis, <italic>Ky</italic> Kyphosis, <italic>SpB</italic> Sspina bifida, <italic>AcR</italic> Achilles tendon retraction, <italic>TFL</italic> Tensor fascia lata, <italic>T-M</italic> Temporo-mandibular, <italic>RSs</italic> Rigid spine, <italic>CFee</italic> Club feet, <italic>LNF</italic> Long narrow face, <italic>HAP</italic> High arched palate, <italic>PrG</italic> Prognathism, <italic>RtG</italic> Retrognathia, <italic>PctE</italic> Pectus excavatum, <italic>HypL</italic> Hyperlaxity, <italic>Kn</italic> Knee, <italic>Eb</italic> Elbow, <italic>n.r.</italic> Not reported</p></table-wrap-foot></table-wrap></p><sec id="Sec12"><title>Morphological findings</title><p id="Par16">We defined &#x0201c;dusty core fibres&#x0201d; the muscle fibres with irregular areas of reddish-purple granular material deposition at GT stain corresponding to large areas of uneven myofibrillar disorganisation at oxidative stains, characterised by blended decreased or/and increased enzymatic activity and devoid ATPase activity (&#x0201c;dusty cores&#x0201d;) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a-f). These dusty core fibres are different from the classic central cores observed in CCD because the last cores are well delimited and have not fuchsine deposit inside the core.<fig id="Fig1"><label>Fig. 1</label><caption><p>DuCD morphological spectrum. Dusty cores: irregular areas of reddish-purple granular material deposition at GT stain (<bold>a</bold>, <bold>d</bold>, <bold>g</bold> and <bold>i</bold>) corresponding to areas of devoid ATPase activity (<bold>c</bold>, <bold>f</bold> and <bold>h</bold>) and decreased or increased enzymatic activity at oxidative stains (<bold>b</bold>, <bold>e</bold> and <bold>l</bold>), sometime occurring in the same core side-by-side (<bold>b</bold> and <bold>e</bold>; arrows) or concentric with &#x0201c;targetoid&#x0201d; appearance (<bold>b</bold>, <bold>i</bold> and <bold>l</bold>; arrowheads). Note type 1 fibre uniformity (<bold>c</bold>, <bold>f</bold> and <bold>h</bold>) and prominent nuclear internalization (<bold>d</bold> and <bold>g</bold>). (<bold>a</bold>-<bold>c</bold>: p12, 28 years; <bold>d</bold>-<bold>f</bold>: p11, 48 years; <bold>g</bold> and <bold>h</bold>: p19, 4 years; <bold>i</bold> and <bold>l</bold>: p24, 1 year)</p></caption><graphic xlink:href="40478_2018_655_Fig1_HTML" id="MO1"/></fig></p><p id="Par17">Dusty cores were the most frequent histopathological lesion, detected in 32 muscle biopsies and confirmed by EM in 30 muscle biopsies (56,6%). We named &#x0201c;Dusty Core Disease&#x0201d; (DuCD) the corresponding group of congenital core myopathy with dusty cores.</p><p id="Par18">Central cores (single or multiple, centrally or peripherally placed) were observed in 10 (18,5%) muscle biopsies, whereas core-rod association was detected in 7 (13%) biopsies. Type1 fibre predominance/uniformity was the main histopathological alteration in 5 (9,2%) muscle biopsies, associated to minimal changes of the myofibrillar network at oxidative stains (type1 predominance &#x0201c;plus&#x0201d;, T1P+). Finally, 2 muscle biopsies were classified as CNM with type1 fibre hypotrophy, both performed at early stages of life.</p><p id="Par19">The number of muscle fibres containing dusty cores ranged greatly from few fibres up to 30-40% of fibres in muscle biopsy.</p><p id="Par20">Dusty cores were consistently associated to type1 fibre predominance or uniformity and prominent nuclear internalization and centralization. Some muscle biopsies presented some supplementary peculiar features: in 3 muscle biopsies (p4, p14, p17) dusty cores were detected only in few (2-5) muscle fibres only after an extensive and careful revision; whereas in 3 others (p14, p15, p21) none or minor nuclear internalization was observed; 3 muscle biopsies (p9, p18, p24) presented a high fibre size variability with hypertrophic and atrophic fibres, fibre slitting, increased connective tissue without necrosis and regeneration (pseudo-dystrophic appearance); five muscle biopsies (p1, p11, p16, p19, p20) showed a prominent nuclear internalization and centralization (CNM-like) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>g,h); one case (p26) showed surprisingly both dusty and central cores. These findings provide the evidence that a certain variability exists among the DuCD morphological spectrum, in which dusty cores represent the unifying lesion.Regardless of these peculiarities, in 14/31 cases (45%) dusty cores presented a &#x0201c;targetoid&#x0201d; appearance in variable amount of muscle fibres (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>i,l).</p><p id="Par21">The IHC study for myofibrillar proteins (desmin, myotilin, &#x003b1;B-crystallin) did not show any specificity in type1 predominance group. By contrast central core and dusty core groups showed an inconsistently positive immunostaining of all three antibodies inside cores (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a-c, g-i), with the only peculiarity for desmin which showed a peripheral halo of cores in some biopsies of CCD group. Likewise, immunofluorescence for RyR1 and DHPR showed an inconstant positivity for central core and dusty core groups, even if in DuCD group positive signal by RyR1 and DHPR did not match (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d-f, l-n). No specificity was observed for type1 predominance group and by a-actinin immunostaining for all groups.<fig id="Fig2"><label>Fig. 2</label><caption><p>Immunoistochemestry and Immunofluorescence of DuCD and CCD. IHC showing positive immunostaining for desmin (<bold>a</bold> and <bold>g</bold>) myotilin (<bold>b</bold> and <bold>h</bold>) and &#x003b1;B-cristallim (<bold>c</bold> and <bold>i</bold>) in both central cores (<bold>a</bold>-<bold>c</bold>) and dusty cores (<bold>g</bold>-<bold>i</bold>). Serial images of NADH and immunofluorescence for RyR1 and DHPR showing positive signal in central cores (<bold>e</bold> and <bold>f</bold>) and positive, but unmatching signal in dusty cores (<bold>m</bold> and <bold>n</bold>). (<bold>a</bold>-<bold>c</bold>: p26, 32 years; <bold>d</bold>-<bold>f</bold>: p40, 25 years; <bold>g</bold>-<bold>i</bold>: p13, 28 years; <bold>l</bold>-<bold>n</bold>: p7, 76 year)</p></caption><graphic xlink:href="40478_2018_655_Fig2_HTML" id="MO2"/></fig></p><p id="Par22">The EM study showed some peculiarities in the DuCD group. In longitudinal sections, the areas of sarcomeric disorganization consisted of cellular debris with sarcomeric fragments of thin and thick filaments devoid of mitochondria. In addition, two abnormal elements were consistently observed: abundant electrodense longitudinally-smeared material and thickened short Z-line darker fragments, sometime superposed (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a,b). These features were evident also in transversal sections (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c), inside areas of disorganization which frequently showed sub-areas of electrodense material deposition, mixed close sub-areas of less osmophilic material. In longitudinal sections, areas of sarcomeric disorganization ranged from few to more than 50 sarcomeres (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). In all cases of dusty core group, smaller areas of sarcomeric disorganization, resembling minicores, were noticed (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). The larger areas of disorganization, possibly corresponding to dusty cores at optic microscopy, had an asymmetric or &#x000ab;star-like&#x000bb; shape, with a longer longitudinal axis and a shorter transversal axis. Sometimes, these areas of disorganization occupy the entire muscle fibre in width (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>e). Interestingly in almost half of cases, several triads duplication or multiplication were detected inside areas of disorganization (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>f). Nevertheless, in all suspected minicore lesions by EM, a deeper analysis, performed with numerous serial sections, revealed the presence of bigger areas of disorganization. Finally, Z-line abnormalities were detected in the majority of cases, including duplication, streaming and smearing across 2-4 sarcomeres.<fig id="Fig3"><label>Fig. 3</label><caption><p>Ultrastructural findings of DuCD. Large irregular areas of sarcomeric disorganization with longer longitudinal axis and shorter transversal axis (<bold>a</bold>) containing abundant electrodense longitudinally-smeared material (arrows) and thickened short Z-line darker fragments (arrowheads), in longitudinal (<bold>a</bold> and <bold>b</bold>) and trasversal (<bold>c</bold>) sections. Smaller areas of sarcomeric disorganization (few sarcomeres) were alsodetected (<bold>d</bold>). Areas of disorganization occupying the entire muscle fibre in width with centralized/internalised nuclei (<bold>e</bold>). Several triads duplication or multiplication were detected inside dusty cores (black arrows). (<bold>a</bold>, <bold>d</bold> and <bold>e</bold>: p10, 34 years; <bold>b</bold>: p17, 34 years; <bold>c</bold> and <bold>f</bold>: p7, 76 year)</p></caption><graphic xlink:href="40478_2018_655_Fig3_HTML" id="MO3"/></fig></p><p id="Par23">Both central core and core-rod groups showed at EM classic unstructured and, less frequently, structured cores. Nemaline rods were consistently observed in all cases of the core-rod group, in clusters of subsarcolemmal areas or scattered in sarcoplasm, frequently in perinuclear areas.</p><p id="Par24">Overall, the ultrastructural study confirmed the optic microscopy classification in 37 out of 39 muscle biopsies analysed. All cases of core-rod were confirmed by EM. Surprisingly in one case of CCD and one case of DuCD no abnormalities were found at the EM study in the specimens analysed.</p><p id="Par25">Concerning patients with more than one muscle biopsy available, the average time between the two biopsies was 12,6 years (range 6-22 years). The first muscle biopsy showed the presence of dusty cores in 3 out of 5 patients, confirmed also in the second muscle biopsy, two of which also showed a &#x0201c;targetoid&#x0201d; appearance and one a pseudo-dystrophic pattern. Interestingly, the first muscle biopsy in 2 cases showed only nuclear centralization in small type1 fibres without any myofibrillar disorganization detected by optic microscopy. Both cases revealed dusty cores in the subsequent muscle biopsies performed some years later.</p><p id="Par26">Finally, based on both the histological and the ultrastructural analysis of all muscle biopsies, the 48 <italic>RYR1</italic>-recessive patients were classified as follow: 26 (54%) patients with Dusty Core Disease (DuCD); 10 (21%) patients with Central Core Disease (CCD); 8 (15%) patients with Cores and Rods (C&#x00026;R) and 5 (10%) with Type1 predominance &#x0201c;plus&#x0201d; (T1P+). All morphological data are summarised in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Morphological data</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Pt</th><th rowspan="2">Morph</th><th rowspan="2">First morph classification</th><th rowspan="2">Age at biopsy</th><th rowspan="2">muscle</th><th colspan="7">Optic microscopy</th><th colspan="3">Electron microscopy</th></tr><tr><th>fibre size variability</th><th>connective tissue</th><th>Nuclei</th><th>fibre type</th><th>cores</th><th>rods</th><th>other findings</th><th>cores&#x02019; characteristics</th><th>length (sarcomeres)</th><th>other relevant findings</th></tr></thead><tbody><tr><td>p1</td><td>DuCD</td><td>CNM+</td><td>45 ds</td><td>n.r.</td><td>+</td><td>+</td><td>I &#x00026; C++</td><td>T1P and A</td><td>dusty</td><td>no</td><td>V, CB</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 30</td><td>SAD (&#x0003e;5 sarcomeres)</td></tr><tr><td>p2</td><td>DuCD</td><td>CNM+</td><td>26 ys</td><td>D</td><td>+</td><td>-</td><td>I &#x00026; C (rare)</td><td>T1U</td><td>dusty</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 30</td><td>TR (up to 4) inside dusty cores; SAD (5-8 sarcomeres); Z-line S+J; occasional aligned thickened Z-line fragments inside small areas of disorganization</td></tr><tr><td>p3</td><td>DuCD</td><td>CNM+</td><td>21 ys</td><td>D</td><td>+</td><td>-</td><td>I &#x00026; C</td><td>T1P and A</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 20</td><td>ZB; AV; Hc; SAD (2-4 sarcomeres); aligned thickened Z-line fragments inside small areas of disorganization in 1 fibre</td></tr><tr><td>p4</td><td>DuCD</td><td>CNM+</td><td>20 days</td><td>n.r.</td><td>+</td><td>+</td><td>I &#x00026; C</td><td>T1P (mild)</td><td>dusty (rare)</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF; multiple</td><td>up to 30</td><td>TR inside dusty cores; SAD (2-4 sarcomeres); Z-line S (2 sarcomeres)</td></tr><tr><td>p5</td><td>DuCD</td><td>CCD</td><td>8 ws</td><td>n.r.</td><td>+</td><td>-</td><td>I</td><td>T1U</td><td>dusty</td><td>no</td><td>V</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p6</td><td>DuCD</td><td>CNM+</td><td>16 ys</td><td>D</td><td>+++</td><td>-</td><td>I &#x00026; C</td><td>T1P and A</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 30</td><td>TR (up to 7) inside dusty cores; SAD (3-6 sarcomeres); mitochondrial electrodense inclusion</td></tr><tr><td>p7</td><td>DuCD</td><td>CCD/MFM</td><td>76 ys</td><td>D</td><td>+</td><td>-</td><td>I &#x00026; C</td><td>T1P</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;20</td><td>TR inside dusty cores; perinuclear lipofuscin; SAD (3-6 sarcomeres)</td></tr><tr><td>p8</td><td>DuCD</td><td>CCD</td><td>23 ys</td><td>Q</td><td>++</td><td>-</td><td>I &#x00026; C</td><td>T1P</td><td>dusty</td><td>no</td><td>CB</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p9</td><td>DuCD</td><td>CCD</td><td>1 ys</td><td>Q</td><td>+++</td><td>++</td><td>I</td><td>T1P</td><td>dusty</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;15</td><td>TR inside dusty cores; SAD (5-6 sarcomeres); Z-line S</td></tr><tr><td>p10</td><td>DuCD</td><td>CMN+/MmD</td><td>34 ys</td><td>D</td><td>+</td><td/><td>I &#x00026; C</td><td>T1P</td><td>dusty</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to-30</td><td>TR inside dusty cores; SAD (4-5 sarcomeres)</td></tr><tr><td>p11</td><td>DuCD</td><td>CNM/CCD</td><td>48 ys</td><td>n.r.</td><td>+</td><td>+</td><td>I &#x00026; C++</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;30</td><td>CNM-like features with perinuclear disorganization and vacuolization and nuclear chains; occasional multiple areas of disorganization in the same fibre; SAD (few sarcomeres)</td></tr><tr><td rowspan="3">p12</td><td rowspan="3">DuCD</td><td>CNM</td><td>15 days</td><td>n.r.</td><td>+++</td><td>-</td><td>I &#x00026; C</td><td>normal</td><td>no</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>CNM+</td><td>4 mos</td><td>D</td><td>+++</td><td>+</td><td>I &#x00026; C</td><td>T1P (mild)</td><td>dusty</td><td>no</td><td>V</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;15</td><td>-</td></tr><tr><td>CNM+</td><td>12 ys</td><td>P</td><td>+</td><td>+/-</td><td>I &#x00026; C</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;20</td><td>-</td></tr><tr><td rowspan="2">p13</td><td rowspan="2">DuCD</td><td>CNM</td><td>6 ys</td><td>n.r.</td><td>+</td><td>-</td><td>I &#x00026; C</td><td>normal</td><td>no</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>CNM+</td><td>28 ys</td><td>D</td><td>+</td><td>+</td><td>I &#x00026; C</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;20</td><td>TR inside dusty cores; inverted triads (T-tub/SR/T-tub); abundant T-tubules; SAD (4 sarcomeres); Z-line J</td></tr><tr><td>p14</td><td>DuCD</td><td>CCD</td><td>9 ys</td><td>D</td><td>+</td><td>+</td><td>normal</td><td>T1P</td><td>dusty (rare) + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 30</td><td>TR (up to 5) inside dusty cores; occasional aligned thickened Z-line fragments inside small areas of disorganization</td></tr><tr><td>p15</td><td>DuCD</td><td>CCD</td><td>3 ys</td><td>n.r.</td><td>+++</td><td>++</td><td>normal</td><td>T1P</td><td>dusty</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p16</td><td>DuCD</td><td>CNM/MmD</td><td>57 ys</td><td>D</td><td>+</td><td>-</td><td>I &#x00026; C++</td><td>T1P</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 30</td><td>Z-line S+J; inside small areas of disorganization; SAD (2-4 sarcomeres)</td></tr><tr><td>p17</td><td>DuCD</td><td>CCD/MmD</td><td>34 ys</td><td>D</td><td>+</td><td>-</td><td>I &#x00026; C</td><td>T1P</td><td>dusty (rare)</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 40</td><td>TR inside dusty cores; aligned thickened Z-line fragments in the peripheral areas of sarcomeric disorganization; SAD (2-3 sarcomeres); Z-line S</td></tr><tr><td>p18</td><td>DuCD</td><td>CCD/C&#x00026;R</td><td>25 ys</td><td>Q</td><td>++</td><td>++</td><td>I</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>lipid</td><td>&#x025ca;-DC containing OFSM and STDF, targetoid</td><td>only transversal</td><td>TR + inverted duplicated triads (T-tub/SR/T-tub)</td></tr><tr><td>p19</td><td>DuCD</td><td>CNM+</td><td>4 ys</td><td>Q</td><td>+</td><td>-</td><td>I &#x00026; C++</td><td>normal</td><td>dusty</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 15</td><td>TR (up to 6) inside dusty cores; SAD (5 sarcomeres)</td></tr><tr><td rowspan="2">p20</td><td rowspan="2">DuCD</td><td>CNM/NM</td><td>7 ys</td><td>TFL</td><td>+</td><td>+</td><td>I &#x00026; C++</td><td>T1P</td><td>dusty</td><td>no</td><td>V, CB</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 30</td><td>TR inside dusty cores; SAD (3-4 sarcomeres)</td></tr><tr><td>NM/vacuolar</td><td>15 ys</td><td>P</td><td>+++</td><td>+/-</td><td>I &#x00026; C</td><td>T1P</td><td>dusty</td><td>no</td><td>V</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p21</td><td>DuCD</td><td>CNM+</td><td>5 ys</td><td>Q</td><td>+</td><td>++</td><td>I (mild)</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td rowspan="2">p22</td><td rowspan="2">DuCD</td><td>CNM+</td><td>21 days</td><td>D</td><td>+</td><td>-</td><td>I &#x00026; C</td><td>T1P &#x00026; A</td><td>dusty</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 15</td><td>SAD (2 sarcomeres)</td></tr><tr><td>CNM+</td><td>12 ys</td><td>D</td><td>+</td><td>+</td><td>I &#x00026; C</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>normal</td><td>-</td><td>-</td></tr><tr><td>p23</td><td>DuCD</td><td>CNM+</td><td>8 ys</td><td>Q</td><td>+</td><td>+</td><td>I</td><td>T1U</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>&#x0003e;20</td><td>SAD (6 sarcomeres)</td></tr><tr><td rowspan="2">p24</td><td rowspan="2">DuCD</td><td>CCD</td><td>15 days</td><td>Q</td><td>+++</td><td>++</td><td>I</td><td>T1P</td><td>dusty</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>CCD</td><td>1 ys</td><td>D</td><td>+++</td><td>++</td><td>I &#x00026; C</td><td>T1P</td><td>dusty + targetoid</td><td>no</td><td>V</td><td/><td>-</td><td>-</td></tr><tr><td>p25</td><td>DuCD</td><td>CNM+</td><td>43 ys</td><td>D</td><td>+</td><td>+</td><td>I &#x00026; C</td><td>T1P</td><td>dusty + targetoid</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF</td><td>up to 20</td><td>TR inside dusty cores; AV; medium-size (9-10 sarcomeres) areas of disorganization</td></tr><tr><td>p26</td><td>DuCD+CCD</td><td>CCD</td><td>32 ys</td><td>D</td><td>+/-</td><td>+</td><td>I</td><td>T1P</td><td>eccentric + dusty (rare)</td><td>no</td><td>-</td><td>&#x025ca;-DC containing OFSM and STDF + UC</td><td>up to 20</td><td>sarcomeric duplication (titin-like); SAD (3 sarcomeres)</td></tr><tr><td>p27</td><td>CCD</td><td>CCD</td><td>16 ys</td><td>D</td><td>+</td><td>-</td><td>normal</td><td>T1P</td><td>eccentric (rare)</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p28</td><td>CCD</td><td>CCD</td><td>n.r.</td><td>Q</td><td>+</td><td>-</td><td>I (mild)</td><td>T1P</td><td>eccentric</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p29</td><td>CCD</td><td>CCD</td><td>23 ys</td><td>D</td><td>+/-</td><td>-</td><td>I</td><td>T1U</td><td>multiple</td><td>no</td><td>-</td><td>SC (multiple)</td><td>&#x0003e;50</td><td>SAD (&#x0003c;10 sarcomeres); Z-line S</td></tr><tr><td>p30</td><td>CCD</td><td>CCD</td><td>5 YS</td><td>Q</td><td>+/-</td><td>+/-</td><td>normal</td><td>T1P</td><td>central</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p31</td><td>CCD</td><td>CCD</td><td>n.r.</td><td>n.r.</td><td>+/-</td><td>-</td><td>normal</td><td>T1P</td><td>eccentric</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p32</td><td>CCD</td><td>CCD</td><td>47 ys</td><td>n.r.</td><td>+/-</td><td>-</td><td>I</td><td>T1P</td><td>multiple eccentric</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p33</td><td>CCD</td><td>CCD</td><td>46 ys</td><td>n.r.</td><td>+</td><td>+</td><td>I</td><td>T1U</td><td>central</td><td>no</td><td>-</td><td>UC</td><td>&#x0003e;30</td><td>-</td></tr><tr><td>p34</td><td>CCD</td><td>CCD</td><td>n.r.</td><td>n.r.</td><td>+</td><td>-</td><td>I</td><td>T1P</td><td>central</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p35</td><td>CCD</td><td>CCD</td><td>35 ys</td><td>D</td><td>+</td><td>+</td><td>I</td><td>T1U</td><td>multiple</td><td>no</td><td>-</td><td>UC</td><td>&#x0003e;50</td><td>small to large areas of disorganization with Z line duplication</td></tr><tr><td>p36</td><td>CCD</td><td>CCD</td><td>76 ys</td><td>D</td><td>+</td><td>+</td><td>I</td><td>T1P</td><td>eccentric</td><td>no</td><td>-</td><td>normal</td><td>-</td><td>-</td></tr><tr><td>p37</td><td>C&#x00026;R</td><td>CCD</td><td>62 ys</td><td>D</td><td>+</td><td>-</td><td>I</td><td>T1P</td><td>dusty-like</td><td>yes</td><td>-</td><td>UC</td><td>&#x0003e;15</td><td>small (&#x0003c;5 sarcomeres) areas of desorganization</td></tr><tr><td>p38</td><td>C&#x00026;R</td><td>CCD</td><td>21 ys</td><td>Q</td><td>+</td><td>+</td><td>I</td><td>T1U</td><td>eccentric</td><td>yes</td><td>-</td><td>UC</td><td>&#x0003e;20</td><td>small (&#x0003c;3 sarcomeres) areas of desorganization</td></tr><tr><td>p39</td><td>C&#x00026;R</td><td>C&#x00026;R</td><td>57 ys</td><td>D</td><td>+/-</td><td>-</td><td>normal</td><td>T1P &#x00026;</td><td>eccentric</td><td>yes</td><td>-</td><td>UC</td><td>&#x0003e;20</td><td>small (&#x0003c;5 sarcomeres) areas of desorganization</td></tr><tr><td>p40</td><td>C&#x00026;R</td><td>C&#x00026;R</td><td>25 ys</td><td>D</td><td>+</td><td>-</td><td>normal</td><td>T1U</td><td>multiple</td><td>yes</td><td>-</td><td>UC &#x00026; SC</td><td>up to 20</td><td>small (&#x0003c;3 sarcomeres) areas of desorganization</td></tr><tr><td>p41</td><td>C&#x00026;R</td><td>C&#x00026;R</td><td>33 ys</td><td>D</td><td>+</td><td>+</td><td>I</td><td>T1U</td><td>eccentric</td><td>yes</td><td>-</td><td>UC &#x00026; SC</td><td>up to 30</td><td>-</td></tr><tr><td>p42</td><td>C&#x00026;R</td><td>CCD</td><td>2 ys</td><td>D</td><td>+</td><td>+</td><td>normal</td><td>T1P</td><td>eccentric</td><td>yes</td><td>-</td><td>UC &#x00026; SC</td><td>&#x0003e;15</td><td>Focal areas of disorganization (2 sarcomeres) of z-line smearing</td></tr><tr><td>p43</td><td>C&#x00026;R</td><td>NM/CMD</td><td>1 day</td><td>n.r.</td><td>++</td><td>++</td><td>I (mild)</td><td>T1P &#x00026; A</td><td>dusty-like</td><td>yes</td><td>-</td><td>UC</td><td>-</td><td>-</td></tr><tr><td>p44</td><td>T1P+</td><td>T1P</td><td>3 ys</td><td>n.r.</td><td>+</td><td>+</td><td>I (mild)</td><td>T1P &#x00026; A</td><td>MFD (mild)</td><td>no</td><td>-</td><td>n.a.</td><td>-</td><td>-</td></tr><tr><td>p45</td><td>T1P+</td><td>T1P</td><td>3 ys</td><td>n.r.</td><td>+</td><td>+</td><td>I</td><td>T1U</td><td>normal</td><td>no</td><td>-</td><td>no</td><td>-</td><td>cisternae enlargement</td></tr><tr><td>p46</td><td>T1P+</td><td>T1P</td><td>2 ys</td><td>D</td><td>+/-</td><td>-</td><td>normal</td><td>T1U</td><td>MFD (rare)</td><td>no</td><td>-</td><td>no</td><td>-</td><td>-</td></tr><tr><td>p47</td><td>T1P+</td><td>T1P</td><td>4 ys</td><td>n.r.</td><td>-</td><td>+</td><td>normal</td><td>T1U</td><td>MFD (mild)</td><td>no</td><td>-</td><td>no</td><td>-</td><td>-</td></tr><tr><td>p48</td><td>T1P+</td><td>T1P</td><td>14 ys</td><td>n.r.</td><td>+</td><td>-</td><td>normal</td><td>T1P</td><td>MFD (mild)</td><td>no</td><td>Alv</td><td>no</td><td>-</td><td>unstructured areas with mitochondria</td></tr></tbody></table><table-wrap-foot><p><italic>DuCD</italic> Dusty core disease, <italic>CCD</italic> Central core disease, <italic>C&#x00026;R</italic> Core-rod myopathy, <italic>T1P+</italic> Type1 predominance &#x0201c;plus&#x0201d;, <italic>CNM</italic> Centronuclear myopathy, <italic>MmD</italic> Multiminicore disease, <italic>MFM</italic> Myofibrillar myopathy, <italic>CMD</italic> Congenital muscular dystrophy, <italic>NM</italic> Nemaline myopathy, <italic>D</italic> Deltoid, <italic>Q</italic> Quadriceps, <italic>P</italic> Paravertebralis muscles, <italic>TFL</italic> Tensor fascia lata, <italic>I</italic> Internalised, <italic>C</italic> Centralised, <italic>T1P</italic> Type1 predominance, <italic>T1U</italic> Type1 uniformity, and <italic>A</italic> Atrophy, <italic>&#x025ca;-DC</italic> Irregular/star-shaped dusty core, <italic>OFSM</italic> Osmophilic filamentous smeared material, <italic>STDF</italic> Short thickened darker fragments, <italic>UC</italic> Unstructured cores, <italic>SC</italic> Structured cores, <italic>SAD</italic> Small areas of myofibrillar disorganization, <italic>TR</italic> Triad replication, <italic>ZB</italic> Zebra bodies, <italic>AV</italic> Autophagic vacuoles, <italic>Z-line S</italic> Streaming; Z-line, <italic>J</italic> Jagging, <italic>Hc</italic> Honeycomb figures</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13"><title>Molecular data</title><p id="Par27">Every patient has at least one variation on each allele of <italic>RYR1</italic> gene&#x000a0;(Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Each variant was identified based on its low frequency (less than 0.5% in database gnomAD). Thirteen variants were not previously reported. Twenty-six hypomorphic variants were found (non-sense, out of frame deletion, splice variant). The others were in frame deletion (p.M4000del), in frame duplication (p.E1651_L1656dup), missense variants and a combination of 3 or 4 variants resulting in the mutant haplotype p.[I1571V;R3366H;Y3933C] or p.[I1571V; R3119H; R3366H; Y3933C] already described [<xref ref-type="bibr" rid="CR10">10</xref>]. Each variant was found in a conserved region (in the vertebrate subphylum). Only L4650P, R2140W, L883P, P4501L and R4179H variations were classified as moderate, a similar type of amino acid change being observed in other species of vertebrate phylum. All the bioinformatic scores lead to consider all these variations as impacting the protein. Each variant was localized on the RyR1 3D structures and 26 variants were predicted to induce destabilisation by foldX software. Other 10 variants, localized on the RyR1 3D structures (in the so-called domains 5gl1 and 5taz), were predicted to induce the loss of nearby interaction. Five variants (N2342S, R4179H, V4842M, E4911K) were predicted to induce no particular change in RyR1 structure at the interaction or steric hindrance level [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The variant V4842M was associated with an additional splice variant. The N2342S has already been associated with a functional defect, the E4911K is located in the triadin interaction motif, the A4946V is located in a transmembrane domain and the R4179H is located in a calcium affinity domain [<xref ref-type="bibr" rid="CR38">38</xref>]. Overall, 17 different missenses variants (40.5%) are located in the bridge solenoid (B-sol) domain (which contains the FKBP binding domain), 2 in the S2S3 domain, 4 in the Csol (5%), 3 in the J sol (7.5%), 5 in the NTD domain (12.5%), 6 in the pore domain (15%), 3 in the pVSD domain (7.5%), 1 in the RYR1&#x00026;2 domain (2.5%), 2 in the SPRY1 (5%), 2 in the SPRY2 (5%), 1 in the SPRY3 (2.5%), 3 in the TaF domain (7.5%) and 1 in undefined regions (2.5%). For the haplotype variant [I1571V; R3366H; Y3933C], the variants were respectively localized in SPRY3, BSol and CSol domains. Among all mutations only 2 were previously associated to MHS (T2206M, R2458C). To note 5 were located in MH1 domain (p.E39K, p.S71Y, p.Q155P, p.G215E, p.R614C), 6 in the MH2 domain (p.T2206M, p.N2283H, p.R2355W, p.M2423K, p.R2435L, p.R2458C) and 17 in the MH3 domain (p.Y3933C, p.M4000del, p.R4179H, p.E4181K, p.A4287_A4289dup, p.P4501L, p.R4564Q, p.L4650P, p.T4709M, p.K4724Q, p.Y4796H, p.L4828R, p.V4842M, p.A4846V, p.M4875T, p.A4906V, p.E4911K). Among all variants only 2 were previously associated to MHS (T2206M, R2458C). According to the ACMG classification, 19 variants were considered as class 5 (pathogenic), 31 variants were classified as class 4 and 19 variants of unknow signification (class3).</p></sec><sec id="Sec14"><title><italic>RYR</italic>1 expression study</title><p id="Par28">RyR1 expression was obtained from 31/54 muscle biopsies: 17 from DuCD group (68%), 7 CCD (70%), 5 C&#x00026;R (62%) and 2 T1P+ (40%). All the patients had reduced expression of RyR1 in muscle tissue (median 40%, range 7-79%, IQR 25-53). Patients with a very large reduction in the amount of RyR1 (&#x0003c;15% of total) were severely affected. An amount as low as 20% resulted only in a moderate phenotype in at least 5 patients. The patients with latest disease onset (&#x0003e;50 years) had more than 50% protein. Patients with MH mutations have a lower reduction in RyR1 amount, estimated at 7 to 9% for the R2458C variant and 11,5% for the T2206M variant. The reduction related to haplotypes ranged between 17-24%. The E4911K variant leads to a RyR1 loss estimation ranging between 22 to 37.5%.</p></sec><sec id="Sec15"><title>Clinical, morphological and genetic correlation</title><p id="Par29">Most of the severe patients belonged to the DuCD group (6/8 patients) compared to CCD and C&#x00026;R (1 patient in each group respectively). Among T1P+ patients, none had severe clinical presentation. Mild clinical phenotype represented the most frequent clinical presentation in CCD and C&#x00026;R (70% and 62,5% respectively). Surprisingly, among T1P+ group, most of patients (80%) had a moderate clinical phenotype and only 1 (20%) a mild presentation. In DuCD group, 12 patients (48%) had a mild clinical phenotype, 8 moderate (32%) and 6 severe (20%) presentation. Nevertheless, given the small sample size, differences observed in clinical severity among different morphological groups were not statistically significant. Most of patients with ocular involvement belonged to DuCD (70%) and T1P+ (20%) groups. Conversely, 56% of DuCD and, surprisingly, 80% of patients of T1P+ group had ocular involvement. Ocular involvement was significantly more frequent in moderate and severe forms (90% and 86%) compared to mild clinical phenotype (24%) (<italic>p</italic>&#x0003c;0.0001).</p><p id="Par30">Percentage of RyR1 expression was significantly lower in patients with disease onset &#x0003c;1 year (range 7-79; median 25.00; IQR 19-38) compared to those with later onset (&#x02265;1 year) (range 18-76; median 51.50; IQR 38.25-57.75) (<italic>p</italic>=0.011) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). An interesting correlation (Kruskal-Wallis test) was also found between clinical severity and <italic>RYR1</italic> expression, with lower RyR1 expression in more severe patients (p=0.016) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). Concerning morphology, the lowest <italic>RYR1</italic> expression was observed in DuCD group (range: 7-63%; median: 32%, IQR 24.0-40.5), compared to CCD (range: 14-76%; median: 47%, IQR 40-52), C&#x00026;R (range: 20-60%; median: 52%, IQR 36.0-58.5) and T1P+ (range: 54-79%) (<italic>p</italic>=0.059). Comparing DuCD group with non-DuCD groups, <italic>RYR1</italic> expression was significantly lower in the former (<italic>p</italic>=0.015) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c,d).<fig id="Fig4"><label>Fig. 4</label><caption><p>Clinical, morphological and genetic correlation. RyR1 expression was significantly lower in patients with an earlier onset (&#x0003c;1 year) (<bold>a</bold>) and more severe clinical presentation (<bold>b</bold>). The lowest RyR1 expression was observed in DuCD group compared to CCD, C&#x00026;R and T1P+ groups alone (<bold>c</bold>) or together (<bold>d</bold>)</p></caption><graphic xlink:href="40478_2018_655_Fig4_HTML" id="MO4"/></fig></p><p id="Par31">Concerning the position of variants across the <italic>RYR1</italic> gene, high prevalence (40,5%) of missense variants in BSol domain was found among the entire cohort of patients regardless of clinical and morphological phenotype. Nevertheless, no significant relationship was found between the position of variant and morphological or clinical phenotype. Interestingly, variants located in the BSol domain and the pore domain were more frequent in DuCD patients (10/19 and 9/12 respectively).</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par32">After a full revision of histopathological and ultrastructural features of 54 muscle biopsies we have reclassified 48 <italic>RYR1</italic>-recessive patients in 4 main categories: DuCD (54%), CCD (21%), C&#x00026;R (15%) and T1P+ (10%). Dusty cores represent the most frequent histopathological manifestation of <italic>RYR1</italic>-recessive myopathies. Dusty cores represent the characteristic and unifying morphological feature in this group and are characterised by the presence of reddish-purple granular material (&#x0201c;dusty&#x0201d;) deposition at GT stain, corresponding to irregular areas of altered enzymatic activity at oxidative stains (&#x0201c;cores&#x0201d;), and devoid of ATPase activity. Unlike classic central cores, which show a sharply demarked ovoidal area devoid of oxidative stains, dusty cores have no sharply demarked borders, no round/ovoidal shape and no regular size. Moreover, reddish purple material deposition has not been reported in classical CCD due to dominant <italic>RYR1</italic> mutations or in <italic>MYH7</italic>-related core disease. In fact, no dusty cores were observed among 154 muscle biopsies of dominant <italic>RYR1-</italic> and 10 of <italic>MYH7</italic>-related myopathies examined in our lab [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par33">Dusty cores range from small cytoplasmic or subsarcolemmal spots to very large areas of sarcomeric disorganization, sometime occupying the entire muscle fibre in transversal sections, which is not a common finding in CCD. These findings are also detected by EM. The areas of sarcomeric disorganization are similar to the unstructured cores of CCD, but with some differences. First, dusty cores never span longitudinally the entire muscle fibres, but mostly range between 10 and 50 sarcomeres in length. Second, unlike the regular width of the core along the muscle fibre in central cores, the disorganized areas in dusty cores are irregular, enlarged in their central part, sometimes conferring an irregular longitudinal shape to the core, sometimes with &#x0201c;star-like&#x0201d; appearance. Third, composition of cores of DuCD group presents 2 main peculiarities compared to CCD: 1) in longitudinal sections, strands of longitudinally-smeared osmophilic material and darker fragments of short thickened Z-line are consistently observed and 2) in transversal sections, these elements are not homogenously distributed in the core area but are usually accumulated in certain regions, leading to sub-areas of dense material deposition close to sub-areas of less osmophilic material, probably corresponding to the peculiar aspect of mixed increased-decreased enzymatic activity at oxidative staining (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). This phenomenon could explain the peculiar side-by-side of increased/decreased activity at oxidative stains and the unmatched immunofluorescence by RyR1 and DHPR, corresponding to the inhomogeneous composition of dusty cores. The presence of some areas of dusty cores intensely stained at NADH and devoid of mitochondria at EM, leads to speculate that material which accumulates inside dusty cores could, at least partially, belong to sarcoplasmic reticulum or other cytoplasmic structures.<fig id="Fig5"><label>Fig. 5</label><caption><p>Inhomogeneous composition of dusty cores. Transversal section of dusty core by EM (<bold>a</bold>) showing sub-area of accumulated osmophilic material (red line) close to pale sub-area (yellow line), possibly corresponding to the peculiar aspect of increased (red line) and decreased (yellow line) enzymatic activity at NADH (<bold>b</bold>)</p></caption><graphic xlink:href="40478_2018_655_Fig5_HTML" id="MO5"/></fig></p><p id="Par34">In all cases of DuCD, dusty cores were consistently associated to smaller areas of sarcomeric disorganization, but surprisingly none of our cases filled the morphological criteria to be classified as MmD. No muscle biopsy presented a multiminicore appearance by optic microscopy, and ultrastructural analysis revealed the presence of larger areas of disorganization. A possible explication of this finding could be that some small areas of disorganization could correspond to the peripheral-side of dusty cores (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Previously reported cases of MmD in <italic>RYR1</italic>-recessive myopathies, had very similar oxidative stains to those observed in DuCD [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, it has been elucidated that morphological features of <italic>RYR1</italic>-recessive MmD are quite different to those of <italic>SEPN</italic>-related MmD [<xref ref-type="bibr" rid="CR13">13</xref>]. In particular, the previously reported cases of <italic>RYR1</italic>-recessive MmD were associated to type1 fibre predominance/uniformity, nuclear centralization and multiple large cores, as observed in our patients, whereas the <italic>SEPN</italic>-related MmD presents typically smaller and multiple boundless cores (&#x0201c;minicores&#x0201d;) [<xref ref-type="bibr" rid="CR13">13</xref>].<fig id="Fig6"><label>Fig. 6</label><caption><p>Star-shaped dusty cores and ultrastructural finding diagram. Longitudinal section of star-like shaped dusty core by EM (<bold>a</bold>). Three-dimensional representation of dusty cores inside muscle fibre (<bold>b</bold>,1). Superficial slides showing small areas of disorganization corresponding to the peripheral-side of dusty core (<bold>b</bold>,2), leading to a possible misdiagnosis with minicores. Deeper analysis revealing the real size of disorganization (<bold>b</bold>,3)</p></caption><graphic xlink:href="40478_2018_655_Fig6_HTML" id="MO6"/></fig></p><p id="Par35">Most of DuCD patients of this study, had been previously interpreted and classified as CNM with some atypical features (CNM &#x0201c;plus&#x0201d;) (Table <xref rid="Tab2" ref-type="table">2</xref>) because, at that time, the internalisation of nuclei was considered the most relevant abnormality in spite of the areas of myofibrillar disorganisation and purple material deposition, since these areas of disorganization seem to appear later. The most frequent associated features were: irregular areas of myofibrillar network alteration, myofibrillar-like aggregates, or fuchsine material deposition. It is noteworthy that all these morphological features have not been reported in <italic>BIN1, DNM2</italic> or <italic>MTM1</italic>-related CNM [<xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, dusty cores have never been detected in muscle biopsies of our series of CNM (7 BIN1, 29 DNM2, 32 MTM1). On the other hand, it&#x02019;s worthy of note that a prominent nuclear internalization and centralization is a constant finding in all cases of DuCD, sometimes manifesting as the main histopathological feature. Nevertheless, also in these cases, a careful revision, consistently detected the presence of dusty cores in variable amount of muscle fibres, confirmed by EM study. Atypical morphological feature in DuCD group, without nuclear internalization or without type1 predominance, may be rarely observed.</p><p id="Par36">Finally, dusty cores should be considered the unifying morphological feature among DuCD spectrum disorder and represent the morphological signature of <italic>RYR1</italic>-recessive myopathy, even when detected in only few fibres.</p><p id="Par37">Few patients had been previously reported in the first paper of Bevilacqua et al. [<xref ref-type="bibr" rid="CR4">4</xref>] in which muscle biopsies shared histopathological lesions consistent with dusty cores. At that time, we were not aware that these lesions could represent a hallmark of <italic>RYR1</italic>-recessive myopathy, as 7 cases represented a small cohort and it could had been an atypical variability of findings in <italic>RYR1</italic>-recessive patients. Only the systematically revision of muscle biopsies in all <italic>RYR1</italic>-recessive cases, allows us to realise that more than 50% of cases had dusty cores (sometimes only in few muscle fibres) in muscle biopsy. For this reason, we considered appropriate to give a specific name (dusty cores) to these lesions, considering it a specific entity among core diseases (dusty core disease). In this context, we identified DuCD as a subgroup of congenital core myopathies and we re-classified many <italic>RYR1</italic>-recessive patients, from CNM (or other morphological diagnosis) to DuCD group.</p><p id="Par38">Taken together, all these considerations, lead to suppose that the cases reported as MmD and CNM related to <italic>RYR1</italic>-recessive mutations, possibly represent specific variant of DuCD spectrum, in which dusty cores could be few, underestimated, or appeared later in life, as occurred in some of our patients. This speculation is also supported by the evidence that ocular involvement is almost systematically present in the DuCD group, as reported in cases with MmD and CNM-related <italic>RYR1</italic>-recessive myopathies [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], and in most severe patients. Most of severe cases belonged to the DuCD group, even if not statistically significant.</p><p id="Par39">Interestingly the lowest level of RyR1 expression was observed in the DuCD group. These findings suggest a close relation between the RyR1 production and clinicopathological consequences. DuCD represent the last end morphological spectrum of <italic>RYR1</italic>- related myopathies. Possibly, a severe <italic>RYR1</italic> haploinsufficiency, as observed in DuCD with respect to the non-DuCD groups, could impair the stability and integrity of excitation-contraction coupling at triads level. Triads replication observed in several DuCD, could be the expression of tentative compensation of an insufficient RyR1 production. Indeed triads replication and T-tubule dilation has been observed also in dihydropyridine receptor (DHPR)-related congenital myopathy [<xref ref-type="bibr" rid="CR34">34</xref>], which is the voltage-gated L-type Ca2+ channel located on the T-tubule-SR interface with RyR1.</p><p id="Par40">As expected, the lowest level of RyR1 production is also associated to the most severe and early onset (&#x0003c;1 year) cases. The presence and stability of RyR1 protein is probably necessary not only for the sarcomeric structure maintenance, but also for the overall muscle function via efficient excitation-contraction coupling.</p><p id="Par41">A last morphological consideration must be done with respect to the T1P+ group. Interestingly ocular involvement and moderate clinical presentation were frequent in T1P+. These findings could suggest a possible relation between T1P+ and DuCD, supporting the idea that T1P+ could represent an early-state of DuCD. This hypothesis is also supported by the observation of two patients (p12, p13) with the first muscle biopsy showing central nuclei with type1 uniformity and atrophy and the second one showing DuCD, suggesting an evolution of the myopathological lesions with the age. Moreover, all T1P+ cases had also some degree of sarcomeric disorganization at muscle biopsy. Nevertheless, the high level of RyR1 expression in T1P+ group makes this hypothesis controversial and leads to consider T1P+ group a separate entity. More data are warranted to confirm or refuse this hypothesis, as only 2 muscle biopsies of T1P+ group were available for the RyR1 expression study.</p><p id="Par42">Genetic data in our cohort confirmed the high prevalence of missense variant in BSol domain in recessive forms of disease, even if lower than previously published data (40.5% vs 84%) [<xref ref-type="bibr" rid="CR8">8</xref>]. Even if variants located in the BSol domain and the pore domain were more frequent in DuCD patients, no significant correlation has been found between the localization of variants and morphology. Finally, the RyR1 expression study leads to re-classify a number of genetic variants according to ACMG as follow: five class 3 &#x0201c;variant of unknown signification&#x0201d; (P4501L, Y4796H, R2458C, R1679H, M2120T) to class 4 (&#x0201c;probably pathogenic&#x0201d;) and four class 4 variants (M4875T, V1207M, R3903Q, E4911K) to class 5 (&#x0201c;pathogenic variants&#x0201d;). Nevertheless, <italic>RYR1</italic> haploinsufficiency might not be the only molecular mechanism to explain the pathophysiology: functional studies (e.g. calcium imaging test) could be helpful to evaluate the impact of each variant on RyR1 pathophysiology even if these approaches are too complex to be tested in routine diagnosis.</p><p id="Par43">Finally, our results represent an emerging evidence in RYR1-recessive myopathies, but restricted to a specific study population, restricted in a monocentric study. More evidences are warranted to support our findings worldwide in other study populations and other laboratories.</p></sec><sec id="Sec17"><title>Conclusions</title><p id="Par44">In conclusion, dusty core is the most frequent histopathological presentation of <italic>RYR1</italic>-recessive myopathies. Dusty cores are the unifying morphological lesion among the DuCD spectrum pathology and represent the morphological hallmark for the recessive form of disease. DuCD is associated to earlier disease onset, severe clinical phenotype and lowest <italic>RYR1</italic> expression in muscle.</p></sec><sec sec-type="supplementary-material"><title>Additional file</title><sec id="Sec18"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40478_2018_655_MOESM1_ESM.xlsx"><label>Additional file 1:</label><caption><p>Full genetic data. (XLSX 470 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>This work has been financially supported by Association Fran&#x000e7;aise contre les Myopathies (AFM-Telethon), Association Institut de Myologie (AIM), Assistance Publique-H&#x000f4;pitaux de Paris, Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, Sorbonne Universit&#x000e9;, University of Strasbourg, Centre National de la Recherche Scientifique, Grant FONDECYT1151383 to JAB, SAPIENZA Universit&#x000e0; di Roma and Fondazione SAPIENZA of Rome.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MG, NBR: study concept, design and supervision, morphological analysis of all patients, acquisition and interpretation of data, manuscript writing and revising, responsibility for the integrity of the study; EL, MB: histoenzymology and immunohistochemistry studies, analysis and interpretation of the data; GB, CL: electron microscopy study; analysis and interpretation of the data; JR, JB, IM, JL, JF: genetic and western blot analysis, analysis and interpretation of the data, drafting and revising manuscript; JAB, EM, SM, FL, ALT: clinical data collection and morphological analysis of some patients, critical revision of manuscript for intellectual content; GA: statistical analysis, critical revision of manuscript for intellectual content; All authors agreed with the final version of the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar2"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abath Neto</surname><given-names>O</given-names></name><name><surname>Moreno C de</surname><given-names>AM</given-names></name><name><surname>Malfatti</surname><given-names>E</given-names></name><name><surname>Donkervoort</surname><given-names>S</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>J</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>JB</given-names></name><name><surname>Foley</surname><given-names>AR</given-names></name><name><surname>Mohassel</surname><given-names>P</given-names></name><name><surname>Dastgir</surname><given-names>J</given-names></name><name><surname>Bharucha-Goebel</surname><given-names>DX</given-names></name><name><surname>Monges</surname><given-names>S</given-names></name><name><surname>Lubieniecki</surname><given-names>F</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Medne</surname><given-names>L</given-names></name><name><surname>Santi</surname><given-names>M</given-names></name><name><surname>Yum</surname><given-names>S</given-names></name><name><surname>Banwell</surname><given-names>B</given-names></name><name><surname>Salort-Campana</surname><given-names>E</given-names></name><name><surname>Rendu</surname><given-names>J</given-names></name><name><surname>Faur&#x000e9;</surname><given-names>J</given-names></name><name><surname>Yis</surname><given-names>U</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><name><surname>Cheraud</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Lornage</surname><given-names>X</given-names></name><name><surname>Mesrob</surname><given-names>L</given-names></name><name><surname>Lechner</surname><given-names>D</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Deleuze</surname><given-names>J-F</given-names></name><name><surname>Reed</surname><given-names>UC</given-names></name><name><surname>Oliveira</surname><given-names>ASB</given-names></name><name><surname>Biancalana</surname><given-names>V</given-names></name><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>B&#x000f6;nnemann</surname><given-names>CG</given-names></name><name><surname>Laporte</surname><given-names>J</given-names></name><name><surname>Zanoteli</surname><given-names>E</given-names></name></person-group><article-title>Common and variable clinical, histological, and imaging findings of recessive RYR1-related centronuclear myopathy patients</article-title><source>Neuromuscul Disord</source><year>2017</year><volume>27</volume><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2017.05.016</pub-id><?supplied-pmid 28818389?><pub-id pub-id-type="pmid">28818389</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amburgey</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Hwang</surname><given-names>JH</given-names></name><name><surname>Tarnopolsky</surname><given-names>MA</given-names></name><name><surname>Bonnemann</surname><given-names>CG</given-names></name><name><surname>Medne</surname><given-names>L</given-names></name><name><surname>Mathews</surname><given-names>KD</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Daube</surname><given-names>JR</given-names></name><name><surname>Wellman</surname><given-names>GP</given-names></name><name><surname>Callaghan</surname><given-names>B</given-names></name><name><surname>Clarke</surname><given-names>NF</given-names></name><name><surname>Dowling</surname><given-names>JJ</given-names></name></person-group><article-title>Genotype-phenotype correlations in recessive RYR1-related myopathies</article-title><source>Orphanet J Rare Dis</source><year>2013</year><volume>8</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-8-117</pub-id><?supplied-pmid 23919265?><pub-id pub-id-type="pmid">23919265</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X-C</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><article-title>The Central domain of RyR1 is the transducer for long-range allosteric gating of channel opening</article-title><source>Cell Res</source><year>2016</year><volume>26</volume><fpage>995</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.89</pub-id><?supplied-pmid 27468892?><pub-id pub-id-type="pmid">27468892</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevilacqua</surname><given-names>JA</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Bitoun</surname><given-names>M</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Monges</surname><given-names>S</given-names></name><name><surname>Lubieniecki</surname><given-names>F</given-names></name><name><surname>Taratuto</surname><given-names>AL</given-names></name><name><surname>Laquerri&#x000e8;re</surname><given-names>A</given-names></name><name><surname>Claeys</surname><given-names>KG</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name><name><surname>Guicheney</surname><given-names>P</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Romero</surname><given-names>NB</given-names></name></person-group><article-title>Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization</article-title><source>Neuropathol Appl Neurobiol</source><year>2011</year><volume>37</volume><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2010.01149.x</pub-id><?supplied-pmid 21062345?><pub-id pub-id-type="pmid">21062345</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharucha-Goebel</surname><given-names>DX</given-names></name><name><surname>Santi</surname><given-names>M</given-names></name><name><surname>Medne</surname><given-names>L</given-names></name><name><surname>Zukosky</surname><given-names>K</given-names></name><name><surname>Zukosky</surname><given-names>K</given-names></name><name><surname>Dastgir</surname><given-names>J</given-names></name><name><surname>Shieh</surname><given-names>PB</given-names></name><name><surname>Winder</surname><given-names>T</given-names></name><name><surname>Tennekoon</surname><given-names>G</given-names></name><name><surname>Finkel</surname><given-names>RS</given-names></name><name><surname>Dowling</surname><given-names>JJ</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>B&#x000f6;nnemann</surname><given-names>CG</given-names></name></person-group><article-title>Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum</article-title><source>Neurology</source><year>2013</year><volume>80</volume><fpage>1584</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182900380</pub-id><?supplied-pmid 23553484?><pub-id pub-id-type="pmid">23553484</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacheux</surname><given-names>M</given-names></name><name><surname>Blum</surname><given-names>A</given-names></name><name><surname>S&#x000e9;bastien</surname><given-names>M</given-names></name><name><surname>Wozny</surname><given-names>AS</given-names></name><name><surname>Brocard</surname><given-names>J</given-names></name><name><surname>Mamchaoui</surname><given-names>K</given-names></name><name><surname>Mouly</surname><given-names>V</given-names></name><name><surname>Roux-Buisson</surname><given-names>N</given-names></name><name><surname>Rendu</surname><given-names>J</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Krivosic</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Lacour</surname><given-names>A</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Faur&#x000e9;</surname><given-names>J</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name></person-group><article-title>Functional Characterization of a Central Core Disease RyR1 Mutation (p.Y4864H) Associated with Quantitative Defect in RyR1 Protein</article-title><source>J Neuromuscul Dis</source><year>2015</year><volume>2</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.3233/JND-150073</pub-id><?supplied-pmid 27858745?><pub-id pub-id-type="pmid">27858745</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>NF</given-names></name><name><surname>Waddell</surname><given-names>LB</given-names></name><name><surname>Cooper</surname><given-names>ST</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>RLL</given-names></name><name><surname>Kornberg</surname><given-names>AJ</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Lillis</surname><given-names>S</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Bushby</surname><given-names>K</given-names></name><name><surname>Guglieri</surname><given-names>M</given-names></name><name><surname>King</surname><given-names>MD</given-names></name><name><surname>Farrell</surname><given-names>MA</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>North</surname><given-names>KN</given-names></name></person-group><article-title>Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion</article-title><source>Human Mutation</source><year>2010</year><volume>31</volume><fpage>E1544</fpage><lpage>E1550</lpage><pub-id pub-id-type="doi">10.1002/humu.21278</pub-id><?supplied-pmid 20583297?><pub-id pub-id-type="pmid">20583297</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>des Georges</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>OB</given-names></name><name><surname>Zalk</surname><given-names>R</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Condon</surname><given-names>KJ</given-names></name><name><surname>Grassucci</surname><given-names>RA</given-names></name><name><surname>Hendrickson</surname><given-names>WA</given-names></name><name><surname>Marks</surname><given-names>AR</given-names></name><name><surname>Frank</surname><given-names>J</given-names></name></person-group><article-title>Structural Basis for Gating and Activation of RyR1</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>145</fpage><lpage>157.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.075</pub-id><?supplied-pmid 27662087?><pub-id pub-id-type="pmid">27662087</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dlamini</surname><given-names>N</given-names></name><name><surname>Voermans</surname><given-names>NC</given-names></name><name><surname>Lillis</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>K</given-names></name><name><surname>Kamsteeg</surname><given-names>E-J</given-names></name><name><surname>Drost</surname><given-names>G</given-names></name><name><surname>Quinlivan</surname><given-names>R</given-names></name><name><surname>Snoeck</surname><given-names>M</given-names></name><name><surname>Norwood</surname><given-names>F</given-names></name><name><surname>Radunovic</surname><given-names>A</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Vrancken</surname><given-names>AFJE</given-names></name><name><surname>van der Pol</surname><given-names>WL</given-names></name><name><surname>de Coo</surname><given-names>RIFM</given-names></name><name><surname>Manzur</surname><given-names>AY</given-names></name><name><surname>Yau</surname><given-names>S</given-names></name><name><surname>Abbs</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Lammens</surname><given-names>M</given-names></name><name><surname>Hopkins</surname><given-names>PM</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Wraige</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>MR</given-names></name><name><surname>van Engelen</surname><given-names>B</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name></person-group><article-title>Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis</article-title><source>Neuromuscul Disord</source><year>2013</year><volume>23</volume><fpage>540</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2013.03.008</pub-id><?supplied-pmid 23628358?><pub-id pub-id-type="pmid">23628358</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>ST</given-names></name><name><surname>Oliveira</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Pereira</surname><given-names>P</given-names></name><name><surname>Barroso</surname><given-names>C</given-names></name><name><surname>Concei&#x000e7;&#x000e3;o</surname><given-names>I</given-names></name><name><surname>Evangelista</surname><given-names>T</given-names></name></person-group><article-title>Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms</article-title><source>Muscle Nerve</source><year>2011</year><volume>44</volume><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1002/mus.22009</pub-id><pub-id pub-id-type="pmid">21674524</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>Leroy</surname><given-names>J-P</given-names></name><name><surname>B&#x000f6;nnemann</surname><given-names>C</given-names></name><name><surname>Haenggeli</surname><given-names>C-A</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Voss</surname><given-names>WD</given-names></name><name><surname>Nivoche</surname><given-names>Y</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Lemainque</surname><given-names>A</given-names></name><name><surname>Voit</surname><given-names>T</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name><name><surname>Guicheney</surname><given-names>P</given-names></name></person-group><article-title>A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene: Central Core Disease</article-title><source>Ann Neurol</source><year>2002</year><volume>51</volume><fpage>750</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1002/ana.10231</pub-id><?supplied-pmid 12112081?><pub-id pub-id-type="pmid">12112081</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Lain</surname><given-names>A</given-names></name><name><surname>Husson</surname><given-names>I</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Farnoux</surname><given-names>C</given-names></name><name><surname>Brochier</surname><given-names>G</given-names></name><name><surname>Lac&#x000e8;ne</surname><given-names>E</given-names></name><name><surname>Beuvin</surname><given-names>M</given-names></name><name><surname>Viou</surname><given-names>M</given-names></name><name><surname>Man&#x000e9;r&#x000e9;</surname><given-names>L</given-names></name><name><surname>Claeys</surname><given-names>KG</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Voit</surname><given-names>T</given-names></name><name><surname>Romero</surname><given-names>NB</given-names></name></person-group><article-title>De novo RYR1 heterozygous mutation (I4898T) causing lethal core-rod myopathy in twins</article-title><source>Eur J Med Genet</source><year>2011</year><volume>54</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2010.09.009</pub-id><?supplied-pmid 20888934?><pub-id pub-id-type="pmid">20888934</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungbluth</surname><given-names>H</given-names></name></person-group><article-title>Multi-minicore Disease</article-title><source>Orphanet J Rare Dis</source><year>2007</year><volume>2</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-2-31</pub-id><?supplied-pmid 17631035?><pub-id pub-id-type="pmid">17631035</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Dowling</surname><given-names>JJ</given-names></name><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>B&#x000f6;nnemann</surname><given-names>C</given-names></name><name><surname>Dirksen</surname><given-names>R</given-names></name><name><surname>Faure</surname><given-names>J</given-names></name><name><surname>Hamilton</surname><given-names>S</given-names></name><name><surname>Hopkins</surname><given-names>P</given-names></name><name><surname>Marks</surname><given-names>A</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name><name><surname>Meilleur</surname><given-names>K</given-names></name><name><surname>Riazi</surname><given-names>S</given-names></name><name><surname>Sewry</surname><given-names>C</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name><name><surname>Voermans</surname><given-names>N</given-names></name><name><surname>Zorzato</surname><given-names>F</given-names></name></person-group><article-title>217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29&#x02013;31 January 2016</article-title><source>Neuromuscul Disord</source><year>2016</year><volume>26</volume><fpage>624</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2016.06.001</pub-id><?supplied-pmid 27377473?><pub-id pub-id-type="pmid">27377473</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Lillis</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Abbs</surname><given-names>S</given-names></name><name><surname>Sewry</surname><given-names>C</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name></person-group><article-title>Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene</article-title><source>Neuromuscul Disord</source><year>2009</year><volume>19</volume><fpage>344</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2009.02.005</pub-id><?supplied-pmid 19303294?><pub-id pub-id-type="pmid">19303294</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>CR</given-names></name><name><surname>Halliger&#x02013;Keller</surname><given-names>B</given-names></name><name><surname>Brockington</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>SC</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Chattopadhyay</surname><given-names>A</given-names></name><name><surname>Mercuri</surname><given-names>E</given-names></name><name><surname>Manzur</surname><given-names>AY</given-names></name><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Laing</surname><given-names>NG</given-names></name><name><surname>Davis</surname><given-names>MR</given-names></name><name><surname>Roper</surname><given-names>HP</given-names></name><name><surname>Dubowitz</surname><given-names>V</given-names></name><name><surname>Bydder</surname><given-names>G</given-names></name><name><surname>Sewry</surname><given-names>CA</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name></person-group><article-title>Autosomal recessive inheritance of <italic>RYR1</italic> mutations in a congenital myopathy with cores</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1212/WNL.59.2.284</pub-id><?supplied-pmid 12136074?><pub-id pub-id-type="pmid">12136074</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Wallgren-Pettersson</surname><given-names>C</given-names></name><name><surname>Laporte</surname><given-names>JF</given-names></name><collab>Centronuclear (Myotubular) Myopathy Consortium</collab></person-group><article-title>164th ENMC International workshop: 6th workshop on centronuclear (myotubular) myopathies, 16-18th January 2009, Naarden, The Netherlands</article-title><source>Neuromuscul Disord</source><year>2009</year><volume>19</volume><fpage>721</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2009.06.373</pub-id><?supplied-pmid 19683444?><pub-id pub-id-type="pmid">19683444</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Hartley</surname><given-names>L</given-names></name><name><surname>Halliger-Keller</surname><given-names>B</given-names></name><name><surname>Messina</surname><given-names>S</given-names></name><name><surname>Longman</surname><given-names>C</given-names></name><name><surname>Brockington</surname><given-names>M</given-names></name><name><surname>Robb</surname><given-names>SA</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Voit</surname><given-names>T</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Bydder</surname><given-names>G</given-names></name><name><surname>Sewry</surname><given-names>CA</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name></person-group><article-title>Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1930</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000188870.37076.f2</pub-id><?supplied-pmid 16380615?><pub-id pub-id-type="pmid">16380615</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Lillis</surname><given-names>S</given-names></name><name><surname>Munteanu</surname><given-names>I</given-names></name><name><surname>Scoto</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Quinlivan</surname><given-names>R</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Manzur</surname><given-names>AY</given-names></name><name><surname>Roper</surname><given-names>H</given-names></name><name><surname>Jeannet</surname><given-names>P-Y</given-names></name><name><surname>Rakowicz</surname><given-names>W</given-names></name><name><surname>Jones</surname><given-names>DH</given-names></name><name><surname>Jensen</surname><given-names>UB</given-names></name><name><surname>Wraige</surname><given-names>E</given-names></name><name><surname>Trump</surname><given-names>N</given-names></name><name><surname>Schara</surname><given-names>U</given-names></name><name><surname>Lochmuller</surname><given-names>H</given-names></name><name><surname>Sarkozy</surname><given-names>A</given-names></name><name><surname>Kingston</surname><given-names>H</given-names></name><name><surname>Norwood</surname><given-names>F</given-names></name><name><surname>Damian</surname><given-names>M</given-names></name><name><surname>Kirschner</surname><given-names>J</given-names></name><name><surname>Longman</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Auer-Grumbach</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>I</given-names></name><name><surname>Bushby</surname><given-names>K</given-names></name><name><surname>Sewry</surname><given-names>C</given-names></name><name><surname>Robb</surname><given-names>S</given-names></name><name><surname>Abbs</surname><given-names>S</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name></person-group><article-title>Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies</article-title><source>Human Mutation</source><year>2012</year><volume>33</volume><fpage>981</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1002/humu.22056</pub-id><?supplied-pmid 22473935?><pub-id pub-id-type="pmid">22473935</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>E</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Kosho</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Mitsuhashi</surname><given-names>S</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>A</given-names></name><name><surname>Koike</surname><given-names>K</given-names></name><name><surname>Nishino</surname><given-names>I</given-names></name><name><surname>Nonaka</surname><given-names>I</given-names></name><name><surname>Furukawa</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name></person-group><article-title>Recessive RYR1 mutations in a patient with severe congenital nemaline myopathy with ophthalomoplegia identified through massively parallel sequencing</article-title><source>Am J Med Genet A</source><year>2012</year><volume>158A</volume><fpage>772</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.35243</pub-id><?supplied-pmid 22407809?><pub-id pub-id-type="pmid">22407809</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieger</surname><given-names>E</given-names></name><name><surname>Vriend</surname><given-names>G</given-names></name></person-group><article-title>YASARA View - molecular graphics for all devices - from smartphones to workstations</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2981</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu426</pub-id><?supplied-pmid 24996895?><pub-id pub-id-type="pmid">24996895</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name></person-group><article-title>InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines</article-title><source>Am J Hum Genet</source><year>2017</year><volume>100</volume><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.004</pub-id><?supplied-pmid 28132688?><pub-id pub-id-type="pmid">28132688</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f8;seth</surname><given-names>S</given-names></name><name><surname>Voermans</surname><given-names>NC</given-names></name><name><surname>Torbergsen</surname><given-names>T</given-names></name><name><surname>Lillis</surname><given-names>S</given-names></name><name><surname>Jonsrud</surname><given-names>C</given-names></name><name><surname>Lindal</surname><given-names>S</given-names></name><name><surname>Kamsteeg</surname><given-names>E-J</given-names></name><name><surname>Lammens</surname><given-names>M</given-names></name><name><surname>Broman</surname><given-names>M</given-names></name><name><surname>Dekomien</surname><given-names>G</given-names></name><name><surname>Maddison</surname><given-names>P</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Sewry</surname><given-names>C</given-names></name><name><surname>Radunovic</surname><given-names>A</given-names></name><name><surname>de Visser</surname><given-names>M</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>van Engelen</surname><given-names>B</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name></person-group><article-title>A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene</article-title><source>J Neurol</source><year>2013</year><volume>260</volume><fpage>1504</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1007/s00415-012-6817-7</pub-id><?supplied-pmid 23329375?><pub-id pub-id-type="pmid">23329375</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marty</surname><given-names>I</given-names></name><name><surname>Robert</surname><given-names>M</given-names></name><name><surname>Villaz</surname><given-names>M</given-names></name><name><surname>De Jongh</surname><given-names>K</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Catterall</surname><given-names>WA</given-names></name><name><surname>Ronjat</surname><given-names>M</given-names></name></person-group><article-title>Biochemical evidence for a complex involving dihydropyridine receptor and ryanodine receptor in triad junctions of skeletal muscle</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>2270</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.6.2270</pub-id><pub-id pub-id-type="pmid">8134386</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name><name><surname>Labarre-Vila</surname><given-names>A</given-names></name><name><surname>Mezin</surname><given-names>P</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name></person-group><article-title>A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>1171</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg121</pub-id><pub-id pub-id-type="pmid">12719381</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name><name><surname>Faure</surname><given-names>J</given-names></name><name><surname>Castiglioni</surname><given-names>C</given-names></name><name><surname>Desnuelle</surname><given-names>C</given-names></name><name><surname>Sacconi</surname><given-names>S</given-names></name><name><surname>Estournet</surname><given-names>B</given-names></name><name><surname>Ferreiro</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>N</given-names></name><name><surname>Laquerriere</surname><given-names>A</given-names></name><name><surname>Lazaro</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>J-J</given-names></name><name><surname>Morava</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Van der Kooi</surname><given-names>A</given-names></name><name><surname>de Visser</surname><given-names>M</given-names></name><name><surname>Verschuuren</surname><given-names>C</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name></person-group><article-title>Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores</article-title><source>Human Mutation</source><year>2008</year><volume>29</volume><fpage>670</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1002/humu.20696</pub-id><?supplied-pmid 18253926?><pub-id pub-id-type="pmid">18253926</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>Lerale</surname><given-names>J</given-names></name><name><surname>Nivoche</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>D</given-names></name><name><surname>MacLennan</surname><given-names>DH</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name></person-group><article-title>An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor</article-title><source>Hum Mol Genet</source><year>2000</year><volume>9</volume><fpage>2599</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.18.2599</pub-id><pub-id pub-id-type="pmid">11063719</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rendu</surname><given-names>J</given-names></name><name><surname>Brocard</surname><given-names>J</given-names></name><name><surname>Denarier</surname><given-names>E</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Pi&#x000e9;tri-Rouxel</surname><given-names>F</given-names></name><name><surname>Beley</surname><given-names>C</given-names></name><name><surname>Roux-Buisson</surname><given-names>N</given-names></name><name><surname>Gilbert-Dussardier</surname><given-names>B</given-names></name><name><surname>Perez</surname><given-names>MJ</given-names></name><name><surname>Romero</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>L</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Faur&#x000e9;</surname><given-names>J</given-names></name><name><surname>Fourest-Lieuvin</surname><given-names>A</given-names></name><name><surname>Marty</surname><given-names>I</given-names></name></person-group><article-title>Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy</article-title><source>Hum Gene Ther</source><year>2013</year><volume>24</volume><fpage>702</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1089/hum.2013.052</pub-id><?supplied-pmid 23805838?><pub-id pub-id-type="pmid">23805838</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>NB</given-names></name></person-group><article-title>Centronuclear myopathies: A widening concept</article-title><source>Neuromuscul Disord</source><year>2010</year><volume>20</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.nmd.2010.01.014</pub-id><?supplied-pmid 20181480?><pub-id pub-id-type="pmid">20181480</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>Clarke</surname><given-names>NF</given-names></name></person-group><article-title>Congenital myopathies</article-title><source>Handb Clin Neurol</source><year>2013</year><volume>113</volume><fpage>1321</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-59565-2.00004-6</pub-id><?supplied-pmid 23622357?><pub-id pub-id-type="pmid">23622357</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Viollet</surname><given-names>L</given-names></name><name><surname>Cortey</surname><given-names>A</given-names></name><name><surname>Chevallay</surname><given-names>M</given-names></name><name><surname>Leroy</surname><given-names>JP</given-names></name><name><surname>Lunardi</surname><given-names>J</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name></person-group><article-title>Dominant and recessive central core disease associated with RYR1 mutations and fetal akinesia</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>2341</fpage><lpage>2349</lpage><pub-id pub-id-type="doi">10.1093/brain/awg244</pub-id><?supplied-pmid 12937085?><pub-id pub-id-type="pmid">12937085</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Malfatti</surname><given-names>E</given-names></name><name><surname>Schaeffer</surname><given-names>U</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Boucebci</surname><given-names>S</given-names></name><name><surname>Mathis</surname><given-names>S</given-names></name><name><surname>Neau</surname><given-names>J-P</given-names></name><name><surname>Monnier</surname><given-names>N</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name><name><surname>Laporte</surname><given-names>J</given-names></name></person-group><article-title>Autosomal dominant eccentric core disease caused by a heterozygous mutation in the <italic>MYH7</italic> gene</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2014</year><volume>85</volume><fpage>1149</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2013-306754</pub-id><?supplied-pmid 24828896?><pub-id pub-id-type="pmid">24828896</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scacheri</surname><given-names>PC</given-names></name><name><surname>Hoffman</surname><given-names>EP</given-names></name><name><surname>Fratkin</surname><given-names>JD</given-names></name><name><surname>Semino-Mora</surname><given-names>C</given-names></name><name><surname>Senchak</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>MR</given-names></name><name><surname>Laing</surname><given-names>NG</given-names></name><name><surname>Vedanarayanan</surname><given-names>V</given-names></name><name><surname>Subramony</surname><given-names>SH</given-names></name></person-group><article-title>A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>1689</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1212/WNL.55.11.1689</pub-id><pub-id pub-id-type="pmid">11113224</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schartner</surname><given-names>V</given-names></name><name><surname>Romero</surname><given-names>NB</given-names></name><name><surname>Donkervoort</surname><given-names>S</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name><name><surname>Munot</surname><given-names>P</given-names></name><name><surname>Pierson</surname><given-names>TM</given-names></name><name><surname>Dabaj</surname><given-names>I</given-names></name><name><surname>Malfatti</surname><given-names>E</given-names></name><name><surname>Zaharieva</surname><given-names>IT</given-names></name><name><surname>Zorzato</surname><given-names>F</given-names></name><name><surname>Abath Neto</surname><given-names>O</given-names></name><name><surname>Brochier</surname><given-names>G</given-names></name><name><surname>Lornage</surname><given-names>X</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><name><surname>Taratuto</surname><given-names>AL</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>J</given-names></name><name><surname>Gonorazky</surname><given-names>H</given-names></name><name><surname>Ramos-Platt</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Phadke</surname><given-names>R</given-names></name><name><surname>Bharucha-Goebel</surname><given-names>DX</given-names></name><name><surname>Sumner</surname><given-names>CJ</given-names></name><name><surname>Bui</surname><given-names>MT</given-names></name><name><surname>Lacene</surname><given-names>E</given-names></name><name><surname>Beuvin</surname><given-names>M</given-names></name><name><surname>Labasse</surname><given-names>C</given-names></name><name><surname>Dondaine</surname><given-names>N</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Deleuze</surname><given-names>J-F</given-names></name><name><surname>Matthews</surname><given-names>E</given-names></name><name><surname>Pakleza</surname><given-names>AN</given-names></name><name><surname>Sewry</surname><given-names>CA</given-names></name><name><surname>Biancalana</surname><given-names>V</given-names></name><name><surname>Quijano-Roy</surname><given-names>S</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Fardeau</surname><given-names>M</given-names></name><name><surname>B&#x000f6;nnemann</surname><given-names>CG</given-names></name><name><surname>Laporte</surname><given-names>J</given-names></name></person-group><article-title>Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy</article-title><source>Acta Neuropathol</source><year>2017</year><volume>133</volume><fpage>517</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1656-8</pub-id><?supplied-pmid 28012042?><pub-id pub-id-type="pmid">28012042</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaaban</surname><given-names>S</given-names></name><name><surname>Ramos-Platt</surname><given-names>L</given-names></name><name><surname>Gilles</surname><given-names>FH</given-names></name><name><surname>Chan</surname><given-names>W-M</given-names></name><name><surname>Andrews</surname><given-names>C</given-names></name><name><surname>De Girolami</surname><given-names>U</given-names></name><name><surname>Demer</surname><given-names>J</given-names></name><name><surname>Engle</surname><given-names>EC</given-names></name></person-group><article-title><italic>RYR1</italic> Mutations as a Cause of Ophthalmoplegia, Facial Weakness, and Malignant Hyperthermia</article-title><source>JAMA Ophthalmol</source><year>2013</year><volume>131</volume><fpage>1532</fpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2013.4392</pub-id><?supplied-pmid 24091937?><pub-id pub-id-type="pmid">24091937</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snoeck</surname><given-names>M</given-names></name><name><surname>van Engelen</surname><given-names>BGM</given-names></name><name><surname>K&#x000fc;sters</surname><given-names>B</given-names></name><name><surname>Lammens</surname><given-names>M</given-names></name><name><surname>Meijer</surname><given-names>R</given-names></name><name><surname>Molenaar</surname><given-names>JPF</given-names></name><name><surname>Raaphorst</surname><given-names>J</given-names></name><name><surname>Verschuuren-Bemelmans</surname><given-names>CC</given-names></name><name><surname>Straathof</surname><given-names>CSM</given-names></name><name><surname>Sie</surname><given-names>LTL</given-names></name><name><surname>de Coo</surname><given-names>IF</given-names></name><name><surname>van der Pol</surname><given-names>WL</given-names></name><name><surname>de Visser</surname><given-names>M</given-names></name><name><surname>Scheffer</surname><given-names>H</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Voermans</surname><given-names>NC</given-names></name><name><surname>Kamsteeg</surname><given-names>E-J</given-names></name></person-group><article-title><italic>RYR1</italic> -related myopathies: a wide spectrum of phenotypes throughout life</article-title><source>Eur J Neurol</source><year>2015</year><volume>22</volume><fpage>1094</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1111/ene.12713</pub-id><?supplied-pmid 25960145?><pub-id pub-id-type="pmid">25960145</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilmshurst</surname><given-names>JM</given-names></name><name><surname>Lillis</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Pillay</surname><given-names>K</given-names></name><name><surname>Henderson</surname><given-names>H</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>CR</given-names></name><name><surname>Ndondo</surname><given-names>A</given-names></name><name><surname>Cloke</surname><given-names>V</given-names></name><name><surname>Cullup</surname><given-names>T</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Boennemann</surname><given-names>C</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Quinlivan</surname><given-names>R</given-names></name><name><surname>Dowling</surname><given-names>JJ</given-names></name><name><surname>Al- Sarraj</surname><given-names>S</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name><name><surname>Abbs</surname><given-names>S</given-names></name><name><surname>Manzur</surname><given-names>AY</given-names></name><name><surname>Sewry</surname><given-names>CA</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name></person-group><article-title>RYR1 mutations are a common cause of congenital myopathies with central nuclei</article-title><source>Ann Neurol</source><year>2010</year><volume>68</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1002/ana.22119</pub-id><?supplied-pmid 20839240?><pub-id pub-id-type="pmid">20839240</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witherspoon</surname><given-names>JW</given-names></name><name><surname>Meilleur</surname><given-names>KG</given-names></name></person-group><article-title>Review of RyR1 pathway and associated pathomechanisms</article-title><source>Acta Neuropathol Commun</source><year>2016</year><volume>4</volume><fpage>121</fpage><pub-id pub-id-type="doi">10.1186/s40478-016-0392-6</pub-id><?supplied-pmid 27855725?><pub-id pub-id-type="pmid">27855725</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>I-TASSER server: new development for protein structure and function predictions</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>W174</fpage><lpage>W181</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv342</pub-id><?supplied-pmid 25883148?><pub-id pub-id-type="pmid">25883148</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Sewry</surname><given-names>CA</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Bushby</surname><given-names>K</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name><name><surname>Roper</surname><given-names>H</given-names></name><name><surname>Rose</surname><given-names>MR</given-names></name><name><surname>Brockington</surname><given-names>M</given-names></name><name><surname>Kinali</surname><given-names>M</given-names></name><name><surname>Manzur</surname><given-names>A</given-names></name><name><surname>Robb</surname><given-names>S</given-names></name><name><surname>Appleton</surname><given-names>R</given-names></name><name><surname>Messina</surname><given-names>S</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>A</given-names></name><name><surname>Quinlivan</surname><given-names>R</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>CR</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name></person-group><article-title>Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>2024</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1093/brain/awm096</pub-id><?supplied-pmid 17483490?><pub-id pub-id-type="pmid">17483490</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sewry</surname><given-names>C</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Zorzato</surname><given-names>F</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Meissner</surname><given-names>G</given-names></name><name><surname>Treves</surname><given-names>S</given-names></name></person-group><article-title>Characterization of recessive RYR1 mutations in core myopathies</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>2791</fpage><lpage>2803</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl221</pub-id><?supplied-pmid 16940308?><pub-id pub-id-type="pmid">16940308</pub-id></element-citation></ref></ref-list></back></article>